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ABSTRACT
Identification and Characterization of Mitochondrial DNA Variants in
Alzheimer’s Disease
Natasha Singh Hamblet
Eastern Virginia Medical School 
and
Old Dominion University 
1995
Director: Fiank J.Castora
Alzheimer’s Disease (AD) is a complex neurodegenerative disorder that affects 
a significant portion of the human population regardless of ethnicity or gender. A 
mitochondrial hypothesis of AD has been proposed based on a number of studies which 
establish altered oxidative phosphorylation (OXPHOS) and ATP synthesis in AD tissue. 
ATP demand is most prevalent in the brain; damage to OXPHOS could severely impair 
brain metabolism, thereby leading to a decline in cognitive function. Four out of five 
complexes in the OXPHOS pathway are partly encoded by mitochondrial DNA 
(mtDNA); thus, this may be a crucial site of lesions that alter brain activity. Within the 
last decade a number of neuromuscular disorders have been found to be associated with 
mutations in mtDNA. AD patients share a number o f similarities with the mitochondrial 
encephalomyopathies such as reduced oxidative metabolism, delayed onset of 
neurological symptoms, and pathological changes that damage tissues with high ATP 
demand. For these reasons we have been studying AD brain tissue for known, as well
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as any uncharacterized, mtDNA mutations.
We examined brain autopsy tissue for deleted mtDNA by PCR-based methods and 
Southern analysis. AD brain tissue was obtained from autopsy-confirmed cases. Using 
a rat brain model system to examine postmortem effects, we found no mtDNA 
degradation after 30 hours at RT by Southern analysis. We then assessed brain tissue 
for the 5 kb deletion (mtDNAM977)) by PCR-based methods. While optimizing 
quantitative techniques we found that serial dilution PCR and kinetic PCR yielded 
different deletion levels although both methods indicated a greater ratio of mtDNAA4977 
in the caudate than in the parietal cortex of a cognitively intact control. By serial 
dilution PCR we determined that AD temporal cortex had a 12 fold greater frequency 
of mtDNAA4977 than controls (0.0628% vs 0.0053%).
Using diagnostic restriction enzyme analysis, we detected the previously described 
point mutation, tRNAEln4336, in one Caucasian AD patient and in none of the controls. 
Biochemical studies indicated that there is a significant decrease in cytochrome c oxidase 
(COX) activity in platelets and brain tissue of AD patients as well as perturbed COX I, 
13 and ID mRNA levels. We examined the mitochondrially encoded COX subunits by 
single strand conformation polymoiphism (SSCP) and DNA sequencing and identified 
thirty two variants. SSCP efficiency was estimated at 80 %. Sixteen of the mutations are 
new mtDNA variants including a moderately conserved phe->leu missense change in 
COX HI at np 9861 which was observed in 4.2% (1/24) of the AD patients and in 0% 
(0/16) of the controls. Further studies will define if this mutation plays any pathogenic 
role in AD or in COX activity suppression.
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CHAPTER I INTRODUCTION
A. BACKGROUND AND SIGNIFICANCE
Alzheimer’s Diseases (AD), the most common dementing illness in humans, is 
a neurodegenerative disorder that currently affects 4 million Americans. These numbers 
are expected to triple within the next fifty years. The cost of caring for AD patients is 
estimated at $40 billion per year (1). Clinically, AD affects memory, language, 
visuospatial pathways, the motor system and induces neuropsychiatric problems. 
Information processing as well as recall is impaired. Initially, only short term memory 
is affected; but as the disease progresses, long term memory is affected as well (2). 
Language problems include difficulty in word list generation, confrontation naming and 
an inability to link phrases together (aphasia) (3). Most family members notice 
personality changes - the patient is either more passive, self centered and agitated and 
in some instances is less reasonable and affectionate (3). Motor system abnormalities 
rarely occur until the later stages of the disease but mild rigidity can occur as well as loss 
of facial expression and grasping (4). Myoclonus and seizures occur in 10-50% of all 
cases (5,6). A number of neurotransmitter systems are affected by AD but the 
cholinergic system and associated pathways such as the nucleus basalis of Meynert 
projection are most altered (7). Substantial cell loss occurs in the pyramidal cells of the 
hippocampus and other limbic areas such as the amygdala. The cerebral cortex shows
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
severe neuronal dysplasia with the temporal, frontal and parietal cortex usually being 
more affected than the occipital cortex (8).
The major pathological change in AD brain is the presence of neurofibrillary 
tangles (NFTs) and amyloid plaques. NFTs are intracellular deposits composed of the 
microtubule associated tau protein whereas the plaques are extracellular deposits of /3- 
amyloid fibrils (9). Mutations in the amyloid precursor protein (APP) gene as well as 
in the /3-amyloid peptide have been linked to familial early onset AD (10,11) and to 
hereditary cerebral hemorrhage with amyloidosis-Dutch type (12). However, familial 
Alzheimer’s Disease (FAD) accounts for only 5% of all cases whereas approximately 
95 % are considered late onset and sporadic in nature. Specific cases of late onset AD 
have been shown to be positively correlated with the apolipoprotein type e 4 allele (either 
heterozygous or homozygous carriers) (13). The frequency of the e4 allele in normal 
cognitive intact controls was found to be 7% in one study (14) but 20 to 30% in another 
study (15). In the study which found a normal frequency of 7%, 57% of the AD 
individuals carried one or more copies of the e 4 allele while 43 % of the AD cases were 
not carriers (14). Thus, despite these advances there are still a significant number of AD 
cases that are neither familial early onset nor sporadic e4 carriers. Where then does the 
current information on Alzheimer’s lead? One needs to rexamine the genetic, 
biochemical and morphological evidence available.
The clinical genetics of AD have been widely studied in an effort to identify 
potential risk factors for the disease. Twin studies have shown that dizygotic twins are 
usually discordant for the disease whereas monozygotic twins are usually concordant for
2
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the disease (16,17). Monozygotic twins tend to have a higher frequency of affected 
relatives. This points to some cases of AD being heritable while others are not. In fact, 
whereas heritable cases linked to APP mutations on chromosome 21 have an age of onset 
between 40 to 50 years (18), 68% - 78% of AD patients have a later age of onset 
between 60 to 84 years of age (19). Clearly advanced age is a major risk factor. Indeed 
it tops the list of risk factors before head trauma, genetic inheritance or advanced 
paternal and/or maternal age (parental age as a risk factor remains controversial) (20,21). 
However no clear mode of inheritance has been defined in the late onset group. Studies 
are further complicated by individuals of advanced age dying of other diseases such as 
cancer or stroke before potentially manifesting symptoms of AD. Thus, it is believed 
that AD is an etiologically heterogeneous disease which in a small number of cases has 
a single genetic basis. In a majority of cases, however, AD may be due to a multiplicity 
of factors similar to cancer, in which one, or more genetic defects present are influenced 
by environmental factors.
While the genetic studies have proven perplexing, biochemical analyses have 
generated a number of informative findings. Most studies have examined cerebral 
oxygen and glucose metabolism in AD patients using Positron Emission Tomography 
(PET) which monitors metabolism. Three main conclusions emerged - the first was that 
global and regional glucose and oxygen metabolism were reduced compared to age- 
matched controls (22). Secondly, the extent of the reduction was regionally variable in 
the four lobes of the cerebral cortex and lastly, the extent of the reduction was correlated 
with the degree of dementia (22). These three conclusions have, for the large part,
3
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remained intact. However, in later studies there often seemed to be discrepancies as to 
whether a reduction or increase in metabolism was occurring. This is due to the use of 
the phrases "glucose production" , "glucose oxidation" and "oxidative metabolism". If 
the production of 14C02 from (U,4-C) glucose is increased (also referred to as a greater 
rate of oxidation of glucose) then this demonstrates a lower oxidative metabolism. In 
other words, glucose consumption is increased in order to compensate for deficient ATP 
production. One of the earliest in vivo brain studies found that the rate of oxidative 
metabolism was decreased (23). Brown et al. using in vivo phosphorous NMR 
spectroscopy found a lower phosphocreatine (PC) to inorganic phosphorous (PJ ratio in 
AD individuals compared to those with multi-infarct dementia, a vascular disease that can 
mimic symptoms of AD. The PC/P; ratio which measures the energy state of a tissue 
indicates a compromised bioenergetic system in AD (24). Sims et al. in a study in brain 
ex vivo (biopsies) found a 39% greater rate of oxidation of glucose in AD brain (25). 
Later, using whole homogenates of brain samples obtained from the biopsy material, they 
measured the rate of oxygen uptake for controls vs an AD group. They found 0 2 uptake 
similar for AD and controls, but the respiratory control index (RCI) was lower in AD 
brain. This result indicates that 0 2 consumption was normal whereas the abnormal RCI 
implicated that uncoupling of the mitochondria was occurring (25). In autopsy tissue 
direct enzymatic studies have found decreases in the activities in the thiamine 
pyrophosphate dependent multisubunit enzymes, pyruvate dehydrogenase and alpha 
ketoglutarate dehydrogenase (26). The activity of other TCA cycle enzymes such as 
fumarase and citrate synthetase was normal, indicating that the decreased activity was not
4
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due simply to a loss of mitochondria (27).
Further studies have been carried out in non-neuronal tissue. Sims et al. studied 
glucose metabolism in cultured skin fibroblasts and found that the production of 14C02 
from (U14-C) glucose was elevated indicating deficient oxidative metabolism while lactate 
production was higher than in control brains (28). On the other hand, they found that 
the production of 14C02 from (U14-C) glutamine was reduced, indicating a high glutamine 
oxidation state. Glutamine is converted to a-ketoglutarate, a TCA cycle intermediate 
which in the process of oxidative decarboxylation produces NADH. NADH then enters 
the electron transport chain. It is generally accepted that oxidation of glucose in 
cultured fibroblasts can be sensitive to experimental conditions. Based on this 
observation, the glucose metabolism findings are difficult to interpret. However, lactic 
acid production was increased, implying problems in oxygen metabolism (pyruvate is 
shunted to lactate production under anaerobic conditions). A benefit of serially passaging 
fibroblast lines however is that materials present in the original sample are eventually 
diluted out. Thus the effects seen are most likely due to a primary change rather than 
some aspect of the original culture such as medication, hormonal levels, etc (29). The 
alteration in glutamine oxidation then can most likely be attributed to a primary defect. 
In muscle Maraini et al. found a higher mitochondrial metabolism rather than the 
reduction seen in fibroblasts (30). This discrepancy was postulated to be due to the 
different metabolic requirements of muscle cells versus fibroblasts with respect to their 
primary substrate for oxygen metabolism; the primary substrate for cultured fibroblasts 
is probably glutamine and not glucose (31). Other groups however have found decreased
5
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glucose and glutamine oxidation in cultured skin fibroblasts from AD patients (32). 
Additional studies have been done in other tissue types such as white blood cells and T- 
cells all of which parallel the alterations in glucose and oxidative metabolism seen in 
brain (33).
Interestingly in a study using normal fibroblasts, an uncoupler of OXPHOS, 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) stimulated the production of the 
Alzheimer specific antigen Alz-50 150 fold over control cells demonstrating that 
oxidative abnormalities can induce some of the pathological changes seen in AD. AD 
fibroblasts cultured even in the absence of CCCP reacted with the Alz-50 monoclonal 
antibody in a greater percentage than in control lines consistent with the measurement of 
an abnormal respiratory control index in AD patients (34).
All of these studies establish altered oxidative metabolism in AD brain and in AD 
non-neuronal tissue. Oxidative metabolism pathways such as oxidative phosphorylation 
(OXPHOS) and electron transport all take place within the organelle considered to be the 
"powerhouse" of the cell, the mitochondria. Morphological studies support the presence 
of abnormal mitochondria in AD brain. Paracrystalline inclusions, granular dense 
bodies, have been observed in AD tissue similar to abnormal mitochondria seen in 
patients suffering from mitochondrial myopathies, neuromuscular diseases caused by 
mutations affecting mitochondrial function (35). Other ultrastructure studies have found 
mitochondria which are granular and dense with large, swollen cristae (36). Thus, the 
initial biochemical and morphological evidence all strongly argue for an inherent problem 
in the mitochondria of Alzheimer’s patients. Furthermore, as biochemical studies have
6
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continued, a direct link to one complex of the oxidative phosphorylation pathway has 
emerged.
An interesting aspect of the mitochondria of all aerobic organisms is that they 
contain their own DNA, a point that as will be described in the following section, could 
explain some of the complex genetics observed in AD.
Human mitochondria contain a compact, intronless, 16,569 kb closed circular 
double stranded DNA molecule that codes for 2 rRNAs, 22 tRNAs, and 13 polypeptides 
(cytochrome c oxidase subunits I,n, HI, cytochrome b, ATPase subunits 6 and 8, and 
7 subunits of the NADH dehydrogenase). All of these endogenously synthesized proteins 
are components of the electron transport chain and therefore are involved in OXPHOS. 
The respiratory chain is composed of 5 complexes, four of which have subunits encoded 
by mitochondrial DNA (mtDNA) whereas the remaining subunits are coded by nuclear 
DNA (see Table 1) (37). Two to ten molecules of mtDNA are present in each 
mitochondrion, thus, each mitochondrion can have a mixture of normal and abnormal 
(mutant) mtDNA (38). This mixed state is termed heteroplasmy. Mitochondria are 
subject to two processes that could lead to changes in the output frequency of mutant and 
normal molecules, random drift and random partitioning (39). Random partitioning 
refers to the process whereby individual organelles will segregate at random during cell 
division. Cells will be created that are dissimilar due to the particular combination of 
mitochondria. However it has been found that a more effective way of producing 
"allelic" changes occurs during the random segregation of individual mtDNA molecules. 
A mutant mtDNA molecule has two pathways during random drift, either the mutation
7
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Table 1
OXPHOS SUBUNITS THAT ARE ENCODED BY MITOCHONDRIAL DNA
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will be lost or the mutation could be fixed leading eventually to a homoplasmic mutant 
state.
During the acrosome reaction that takes place prior to fertilization no paternal 
mitochondria are transmitted to the zygote, thus, one manner of inheriting mutant 
mtDNA is through the maternal lineage. Homoplasmic mutations usually result in 
immediate, overt problems in oxidative capacity. On the other hand heteroplasmic 
mutations cause a much slower progression of symptoms. This would fit in with the 
progressive disease course observed in AD. The threshold level at which disease occurs 
is dependent on three factors: percentage of mutant mtDNA, tissue type affected and age 
of the individual (40). An abnormal phenotype is expressed when a combination of these 
factors causes levels to decline beyond normal cellular functioning. "Cellular 
functioning" is defined by the oxidative demands of individual cells or organs; 
toxicological studies done by Wallace place cerebral cortex as the primary areas 
dependent on mitochondrial energy followed by type I skeletal muscle, auditory pathway, 
cerebellum, brain stem and heart (41). The brain, which has the highest content of 
mtDNA per gram of mitochondria (42), is at the top of this pyramid. Thus, one can see 
how a mutation that affects mitochondrial function can have severe consequences on brain 
functioning. This is especially true for neuronal transmission and the synthesis of 
neurotransmitters, two processes that are highly dependent on ATP production (43,44) 
and both of which are perturbed in Alzheimer’s.
Early opinion believed that since normal mtDNA was abundant, there was no 
threat of disease due to mutant mtDNA. Within the last decade however a subset of
9
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mitochondrial myopathies and mitochondrial encephalomyopathies have been found to be 
associated with point mutations in the mitochondrial genome. These include Leber’s 
Hereditary Optic Neuropathy (LHON) (45), Neurogenic Muscle Weakness, Ataxia,and 
Retinitis Pigmentosa (NARP) (46), Leigh’s Syndrome (47), Myoclonic Epilepsy and 
Ragged Red Fiber (MERRF) (48) and Mitochondrial Encephalomyopathy with Lactic 
Acidosis and Stroke Like Episodes (MELAS) (49). These diseases were initially linked 
to a mtDNA defect due to respiratory chain deficiencies and evidence of maternal 
inheritance. That a mtDNA point mutation was indeed the culprit in these diseases was 
still controversial. The coup de grace was the development of an elegant system for the 
study of mtDNA mutations. Cell lines were developed that contained no mtDNA. These 
cells were termed rho zero, p°, after yeast mutants that had lost their mtDNA but not 
their mitochondria (39). Mitochondria from patients harboring either the MERRF 
tRNAlys mutation at position 8344 or, the MELAS tRNAlcu transition at position 3243 
were fused with p° cells. The mtDNA mutations associated with MERRF and MELAS 
transferred respiratory chain abnormalities to the p° cells analogous to deficiencies seen 
in the respective patients (50,51,52). Interestingly, AD patients share some clinical 
characteristics of mitochondrial encephalomyopathy patients; myoclonus and epilepsy 
have been reported in some of the later stages of AD (5,6) and a study using single 
photon emission computed tomography (SPECT) found reduced blood flow in a MELAS 
patient similar to the pattern seen in AD (53).
Advanced age has been found to be one factor that predisposes an individual to 
a second type of mtDNA alteration - deletions. As mentioned age is the number one risk
10
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factor for AD. Deletions that span over 40% of the mitochondrial genome have been 
found in normal aged liver, heart, skeletal muscle and brain (54,55,56,57,58,59). They 
have also been implicated in late onset type II Diabetes Mellitus (60) as well as in 
acquired deafness (61). The mitochondrial myopathy Keams-Sayre Syndrome (KSS) is 
due to a 5 kb deletion in mtDNA (62,63) and is referred to as the "common deletion" 
since it is found in many normal aged tissues. The KSS deletion which deletes 5 tRNAs 
and 5 protein genes increases with age in normal individuals but is elevated almost 1000- 
fold in KSS. KSS is a systemic disorder that is usually fatal and is marked by 
opthalmoplegia, onset before age 20, ataxia and ragged red fibers (due to overly 
proliferative mitochondria). Most deletions are believed to be generated at tandem repeat 
sequences between the two origins of replication (termed the "hotspot" area) by a 
slippage mispair mechanism (Fig 1) (64). During replication part of the mitochondrial 
genome is single stranded. At a small region of complementarity, single stranded 
sequences hybridize forming a loop structure that is later excised. Few deletions have 
been detected in the non-hotspot or minor region. The production of a deletion represents 
another way, besides maternal inheritance, that a mtDNA mutation is generated - a 
sporadic alteration in a single individual.
MtDNA is extremely susceptible to the generation and accumulation of sporadic 
point mutations. Mitochondria do not contain efficient excision/repair systems similar 
to the nucleus although the presence of DNA ligases (65), endonucleases (66) and 
glycosylases (67) do hint at a limited excision repair system (68). Uracil glycosylases 
do correct cytosine deamination but do not have excision repair systems to correct 5-
11
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Figure 1
MITOCHONDRIAL GENOME MORBID DELETION MAP
Map depicting deletions that have been detected in mtDNA. The * indicates the 
KSS or common deletion as it is known. Note that all of these deletions occur 
between the origin of heavy strand replication (Oh) and the origin of light strand 
replication (Ol). This is considered to be the "hotspot" or area that deletions 
predominate.
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methyl cytosine deamination (69). The gamma polymerase which is responsible for 
mtDNA replication incorporates an incorrect nucleotide 1 every 8000 bp as compared to 
1 per 30,000 bp for the alpha polymerase (70). A lack of protective histones around the 
mitochondrial genome further increases susceptibility to DNA damaging agents. All of 
these factors are believed to cause mtDNA to have a mutation rate that is 10 to 17 times 
that of the nuclear genome (71). Any of these somatic mutations can occur at different 
intervals of human development from embryogenesis throughout adult life. Thus, the 
development of point mutations in the mitochondrial genome could explain the sporadic 
nature of some cases of late onset AD that are believed to have a polygenic mode of 
inheritance.
Primary genetic alterations such as point mutations and deletions are not the only 
type of changes that occur in mtDNA with advanced age. Epigenetic changes such as 
hydroxylation, peroxidation, deamination anddepurination may damage the mitochondrial 
genome. Oxidative damage of the mtDNA by reactive oxygen species is believed to be 
one major aspect of cellular injury and therefore aging (72,73). Approximately 1 % of 
the oxygen used in the mitochondria is converted to the highly reactive superoxide radical 
0 {  (74). Lipid peroxidation likewise induces mtDNA damage (75). Oxidative damage 
is observed by measuring the oxidized nucleoside, 8-hydroxydeoxyguanosine (8-OHdG). 
The presence of 8-OHdG is a result of oxidative damage since the adduct is due to base 
oxidation by the free radical, OH'. It was found to be .02% in persons under age 55 
whereas in subjects over 65 the level increased at a rate of 0.25% per decade (76). 
Additionally, in Alzheimer’s brain, the level of 8-hydroxydeoxyguanosine was increased
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significantly three-fold over age matched controls (77). The hypothesis that mtDNA is
susceptible to free radical attack was first suggested by Harman (78) who believed that
oxidative damage occurred in all cell types. However Miquel proposed that mtDNA
damage and subsequent cell aging only occurred in differentiated (somatic) tissues and
not in fast replicating cells. As Miquel stated:
"Under normal physiological conditions replicating cells in the stem cell 
compartment and elsewhere do not suffer oxidation stress and resulting organellar 
injury, because of the relatively low rates of oxygen utilization in their 
mitochondria. By contrast, differentiated cells (especially fixed-postmitotic 
cells, such as neurons) sustain mtDNA mutation, inactivation or loss owing to the 
high mitochondrial respiration (with concomitant oxygen radical release) 
needed to support their specialized physiological work (74)."
While mtDNA replication can take place without cytokinesis or karyokinesis (79)
the turnover of mtDNA is greater in highly proliferative tissue. Thus, mtDNA in neurons
is in an ideal environment for the generation and accumulation of mutations. Ageing
therefore would only compound the oxidative problems that are already taking place by
a decreased ability to remove reactive oxygen species (67). Oxidative damage to mtDNA
then may play an etiological role in age related neurodegenerative diseases such as
Alzheimer’s Disease.
Alzheimer’s Disease therefore fits a number of criteria for establishing a defect
in the mitochondrial genome:
1. MtDNA is susceptible to the generation of sporadic mutations. The majority
of AD cases are sporadic showing no linkage despite many attempts at pedigree
analysis.
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2. Late onset AD is an age -related brain disorder. A number of age-associated 
mtDNA alterations have been observed in tissues with high oxidative demand such 
as brain. These mutations have been shown to increase as we age, thus, the 
accumulation of mutations fits the slow progressive disease course observed in late 
onset AD.
3. The population of normal and mutated mtDNA can drift towards entirely 
mutant or normal mtDNA or it can exist as a mixture o f varying proportions of 
mutant and normal mtDNA. The threshold level at which symptoms are 
manifested are in part dependent on the mosaic pattern o f expression determined 
by the mtDNA heteroplasmy; mitochondrial genetics could explain the delayed 
and altered gradients of cognitive deficits observed in different patients.
This hypothesis is further supported by biochemical studies which have found a 
deficiency in Complex IV (cytochrome c oxidase) of the respiratory chain in AD. 
Reduced activity of Complex IV was originally observed in platelets of AD patients 
(80,81) but a 17 to 26% reduction was later demonstrated in temporal and frontal cortex 
(82). This finding by Kish et al. was substantiated by another group that found 
cytochrome c oxidase (COX) activity to be severely defective in AD brain although 
Complexes I, II and in  also showed some depressed activity (83). Three of the thirteen 
COX subunits COX I, COX II and COX HI are encoded by mtDNA (Table 1). Since 
cytochrome c oxidase consists of subunits that are encoded by both nuclear DNA as well
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as mtDNA it is entirely possible that the metabolic deficiencies are linked to a nuclear 
DNA defect, however, an investigation of mRNA levels for COX I, COX n  and COX 
m  found a reduction in the COX I and COX in  message levels in the temporal cortex 
of brain autopsy tissue from Alzheimer’s patients (84). This suggests a possible 
alteration directly in these mtDNA encoded subunits.
In fact, recently a mutation in mtDNA encoding tRNAEln has been reported to be 
associated with AD in as many as 3.2% of the cases examined (85). Additionally a 12s 
rRNA 9 bp insertion, a 16s rRNA3196 variant, and an NADH dehydrogenase subunit l 3397 
base change were detected in various AD patients (85) although these mutations have to 
be further characterized to determine what their relevance, if any, is in the pathogenesis 
of the disease. The possibility that other mtDNA mutations are associated with AD 
requires further investigation, especially those that may be age related such as deletions 
as well as a search for mutations in the cytochrome c oxidase complex.
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B. STATEMENT OF PROBLEM
Alzheimer’s Disease is a complex neurodegenerative disorder that affects a 
significant portion of the human population regardless o f ethnicity or gender. Despite 
advances in understanding the early onset form of the disease the etiological agent in the 
majority of the sporadic late onset cases remains less well understood. A mitochondrial 
hypothesis of AD has been proposed based on a number o f studies which establish altered 
oxidative metabolism in AD tissue. Mitochondria are cellular organelles that consume 
90% of all oxygen incorporated and convert 0 2 into cellular energy in the form of ATP. 
Of all the organs that require ATP for vital functioning, demand is most prevalent in the 
brain. Oxidative phosphorylation (OXPHOS) is a process that drives ATP synthesis 
across the inner mitochondrial membrane. Damage to OXPHOS proteins could severely 
impair brain metabolism thereby leading to a decline in certain cognitive functions. Four 
out of five complexes in the OXPHOS pathway are partly encoded by mtDNA thus this 
may be a crucial site of lesions that alter brain activity. Within the last decade a number 
of neuromuscular disorders, such as certain mitochondrial myopathies, have been found 
to be associated with mutations in mtDNA. These include MERRF, MELAS, LHON, 
LEIGH’S SYNDROME, NARP and KSS. AD patients share a number of similarities 
with the mitochondrial encephalomyopathies such as reduced oxidative metabolism, 
delayed onset of neurological symptoms often into late adulthood, slow progression and 
pathological changes that damage specific tissues with high ATP demand.
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The overall aim of this study is to determine the role that mtDNA plays in 
Alzheimer’s disease which could yield valuable information on etiology, the success of 
treatments that target OXPHOS deficiencies and potential diagnostic markers.
The investigation of mtDNA in AD uses tissue obtained from autopsy confirmed 
cases. The samples are frozen in liquid nitrogen immediately after autopsy yet variability 
exists in postmortem time. The initial phase of this study will determine by Southern 
analysis whether any gross mtDNA alterations are induced by postmortem tissue decay 
using a rat brain model. Southern analysis is effective at detecting deletions in patients 
with mitochondrial myopathies because a large percentage of the patients mtDNA is 
affected. However, Southern analysis does not provide the level of sensitivity necessary 
for measurement of deleted mtDNA in normal aged tissue. Sensitivity can be increased 
by using PCR-based methods. Thus current methods such as serial dilution PCR and 
kinetic PCR will be compared for consistency. Subsequently, AD patient mtDNA will 
be analyzed for the presence of the KSS deletion as well as for any novel deletions in the 
minor region of the mitochondrial genome.
The second phase of this study deals with the screening of mtDNA for point 
mutations in different regions of the genome but primarily in the COX I,H and HI 
subunits. Restriction fragment length polymorphism (RFLP) analysis will be used to 
detect known mtDNA mutations whereas new variants will be identified by single strand 
conformation polymorphism (SSCP). Conditions for SSCP will first be optimized. The 
appropriate genes will be PCR amplified, restriction digested then electrophoresed on 
SSCP gels and polymorphisms will be confirmed by dideoxy sequencing.
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The final stage of this research aims to develop an in vitro neuronal system for 
the study of mtDNA mutations. p° cells have previously been produced for this purpose. 
Originally the p° line was derived in cancer cells such as HeLa. A rat neuronal cell line 
that undergoes differentiation upon addition of nerve growth factor will be used in an 
effort to generate a novel p° system that can be used in the study of mtDNA mutations 
in neurological disorders. Progress on developing the rat p° will be described.
All of these studies will enable researchers to better define the significance, if 
any, of mtDNA abnormalities in Alzheimer’s Disease.
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CHAPTER n  MATERIALS AND METHODS
A. EQUIPMENT
Tissue culture was done in a Purifier Class n  Safety Cabinet (Labconco and SteriGard), 
C 02 tanks were obtained from Norfolk Welders. Cell incubator was a Nuaire ER 
Autoflow, water baths were Precision Model 182 and Lab Line, the microscope was an 
Olympus CK2, the table top centrifuge was an EEC Centra MP4R, the spectrophotometer 
for quantitating DNA was an LKB Ultraspec II and the laser densitometer was a 
Pharmacia LKB Ultroscan XL. The thermal cycler used for PCR was a Bamstead 
Thermolyne Temp Tronic, the DNA synthesizer was a Cyclone Plus (Biosearch Inc.), 
power supplies used for sequencing were a BioRad Power Pac 3000 and an IBI MBP 
3000D and the sequencing apparatti was from EBI. The dry bath incubator was from 
Fisher Scientific, the gel dryer was a BioRad Model 483, the speed-vac concentrator and 
refrigerant were from Savant and the crosslinker used for Southern analysis was a 
Stratagene UV Stratalinker 1800. All microfuges were from Beckman, balances were 
from Mettler, the land camera for all photographic work was a Polaroid MP4 and the 
UV transilluminator was from UVP.
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B. MATERIALS
Taq polymerase used was from Perkin Elmer Cetus and Promega. The T4 polynucleotide 
kinase, Proteinase K and the finol kit were from Promega. All radioisotopes were from 
NEN. Various restriction enzymes were from Promega, Boehringer Mannheim and 
New England BioLabs. DNA molecular weight markers were from Promega. Primer 
synthesis kits and purification columns were from Milligen/Millipore, reagents for 
buffers were mainly from Fisher Scientific, and for mutation detection the MDE- 
Hydrolink gel was from J.T. Baker/A.P.Biochem. Silver Stain and Silver Stain Plus 
were from BioRad. For PCR purification Magic PCR Purification kits from Promega and 
Prep-a-Gene purification kits from Bio-Rad werre used. The Genius Chemiluminescent 
Detection kit was from Boehringer Mannheim. For Southern transfer MagnaGraph 
nylon membrane from Schleicher and Schuell was used. Tissue culture reagents such as 
RPMI 1640 powder, trypsin, antibiotics were from Gibco-BRL while the fetal bovine 
serum was from Hyclone and the donor horse serum was from JRH Biosciences. 
Disposables were from Fisher, Sarstedt and Costar) and polylysine, 6-thioguanine, 
Fungizone, pyruvate and uridine were from Sigma. Polaroid type 55 + /- film was from 
Qualex, Fuji RX autoradiography film Agarose High EEO, polyacrylamide and bis- 
acrylamide powder were from Fisher. SigmaCote from Sigma was used to siliconize 
plates.
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C. RAT mtDNA AUTOLYSIS
Sprague Dawley rat brains were obtained from Dr. Dieter Bartschat of the Department
of Physiology at Eastern Virginia Medical School. Veterinary care was provided by the
Division of Animal Resources, Medical College of Hampton Roads. One to two month
old rats were sacrificed by decapitation and brains were immediately placed in
mitochondrial isolation buffer B (see Fig 2.) and frozen at -70°C. Since three rats were
sacrificed at a time rat brains were collected over a period of 2 weeks and frozen at -
70°C until 12 intact brains (minus the hippocampus which was being used for another
experiment) were obtained for 6 time points. The experiment was repeated with another
complete set of rat brains. Samples were then thawed on ice, weighed and placed in
sterile weighing boats at RT for 0, 6, 12, 24 and 30 hours. At individual time points
samples were placed in 2 mis Buffer B until DNA isolation. The average brain mass was
«
1.124g +/-0.013 and the amount of DNA recovered as determined by 
spectrophotometry ranged from 70 to 90 fig s.
1. Rat brain mtDNA isolation - Total DNA enriched for mtDNA was isolated from 
frozen rat brains using the techniques of Swierczynski (86) and Drouin (87) with 
modifications for the analysis of small amounts of tissue. The techniques were modified 
by omitting the cesium chloride differential centrifugation step. After proteinase K 
digestion, samples were phenol/chloroform extracted, ethanol precipitated, resuspended 
in 10 mM Tris/1 mM EDTA (TE) then dialyzed in TE overnight, (see Fig. 2 for
22
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Figure 2
MtDNA ISOLATION FROM SMALL AMOUNTS OF BRAIN TISSUE 
Mitochondrial DNA isolation procedure used for milligram amounts of brain tissue.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1. Weigh samples. Homogenize in Buffer B, 1 ml/100 mg of tissue (.25 M 
sucrose/5mM EDTA/lOmM Tris-HCL pH 7.4) at 7 RPM using a teflon pestle.
2. Centrifuge homogenate at 1000 x g for 10 minutes. Discard nuclear pellet.
3. Centrifuge supernatant 16,000 x g for 10 minutes.
4. Resuspend mitochondrial fraction in 2mls Buffer C (.25 M sucrose/lOmM Tris- 
HCL, pH 7.4).
5. Centrifuge 500 x g  for 10 minutes. Discard pellet.
6. Sediment supernatant 7000 x g for 10 minutes.
7. Resuspend pellet in 1 ml Buffer D (25mM Tris pH 7.5/50mM EDTA/75mM 
NaCl).
8. Lyse with lOmg/ml Proteinase K (lmg/ml final), 20% SDS (1% SDS final) for 
5 hours at 50°C or at 37°C overnight.
9. Phenol/Chloroform extract (1:1 volume, aqueous:organic) to remove protein.
10. Ethanol precipitate at -20°C overnight using 3M NaOAc (1/10 Volume) and 95 % 
Ethanol (2x Volume).
11. Sediment precipitated DNA at 12,000 RPM for 30 minutes.
12. Wash pellet with 70% Ethanol, dry and resuspend in 10 mM Tris (pH 7.5), ImM 
EDTA and store at 4°C.
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complete description).
2. Southern transfer of Rat mtDNA
Approximately 2 fig of total rat DNA enriched for mtDNA was restriction digested with 
either Bam HI (which cuts at np 9361 and np 14433) or Xho I (which cleaves at np 
11178) and loaded onto a 0.8% TAE agarose gel and electrophoresed at 100 V until the 
xylene cyanol was three fourths of the way into the gel (~ 7  hours). Bands were 
visualized with ethidium bromide then prepared for transfer. The gel was depurinated 
in 0.25 N HCL for exactly 10 minutes, denatured twice (30 minutes each in 1.5 M 
NaCL, .5 M NaOH) then neutralized twice, (30 minutes each in 1 M Tris-HCL pH 8.0,
1.5M NaCl). The gel was transfered overnight using Southern transfer (88) in 10X SSC 
onto a nylon membrane (S & S Magna Graph) that was pretreated for 1 hour in 10 X 
SSC. The next day the DNA was crosslinked (Stratagene Stratalinker) at 120,000 
^joules/cm2.
3. Chemiluminescent Detection
Cesium chloride purified placental mtDNA (see Fig. 3) to be used as probe was prepared 
according to the Genius™ System protocols (Boehringer Mannheim) with the following 
note: placental mtDNA was random primer labeled for 11 hours at 37°C but was not 
ethanol precipitated after labeling. The mass of the labeled probe determined as 
described by the manufacturer was estimated to be 400 ngs. Three membranes were 
prehybridized (.5x SSC, 1% blocking reagent, 0.1% N-lauroyl sarcosine, 0.02% SDS)
24
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Figure 3
PLACENTAL MtDNA ISOLATION
DNA isolation procedure used to purify mitochondrial DNA from human placenta.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HUMAN PLACENTA SHOULD BE PREPARED WITHIN 30 MINS OF
DELIVERY
1. Drain blood from placenta; remove membranes with sterile scalpel and weigh 
tissue.
2. Rinse tissue 3x’s in Buffer A (0.9% NaCL/5 mM EDTA/10 mM Tris-HCL pH
7.4). ["600 ml/placenta]
3. Rinse tissue 2x’s in Buffer B (0.25 M sucrose/5 mM EDTA/10 mM Tris pH 7.4).
[400 ml/placenta]
4. Grind tissue in meat grinder.
5. Suspend in isolation media (Buffer B). ["100 g tissue in 200 ml]
6. Homogenize in glass blender.
7. Filter homogenate through three layers surgical gauze.
8. Centrifuge 1000 x g or 10 min. Discard pellet.
9. Sediment supernatant 10,000 x g for 10 min. [crude mitochondria]
10. Resuspend pellet in 70 ml Buffer C (0.25 M sucrose/10 mM Tris pH 7.4).
11. Centrifuge 500 x g for 5 min. Discard pellet.
12. Sediment supernatant 10,000 x g for 10 min.
13. Wash pellet once with 20 ml Buffer C.
14. Sediment 10,000 x g for 10 min. [~50 mg mtprotein/lOOg tissue]
15. Resuspend in 10 ml 25 mM Tris pH 7.5/50 mM EDTA/75 mM NaCl.
16. Lyse with 1.7 ml 10% SDS at 37°C for 5 min.
17. Add 3 ml 7 M CsCl and cool lysate on ice for 10 min.
18. Remove cesium dodecyl sulphate precipitate by centrifugation - 20, 000 x g for 
10 min.
19. Add ethidium bromide to 500 ug/ml.
20. Adjust refractive index to 1.39 with solid CsCl.
21. Centrifuge in Vti65.1 for 16 hours at 55 k at 20°AC.
22. Collect lower band and recentrifuge at same conditions for 4 hours at 55k.
23. Collect lower band and extract with CsCl-saturated isopropanol.
24. Transfer to 30 ml corex tube and add lx volume water and 2x final volume
ethanol. Precipitate on ice for 30 min or overnight at 20°C.
25. Centrifuge at 10,000 RPM for 30 minutes at 4°C in JA-20 rotor.
26. Pour of supernatant and save.
27. Dissolve mtDNA pellet in 10 mM Tris (pH 7.9)/l mM EDTA and store at 4°C.
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at 65°C for 3 hours in a seal-a-meal bag in a rocking shaker. Afterwards, the same 
prehybridization solution was emptied into a 50 ml conical tube and the denatured probe 
was added directly for a final concentration of 10 ng/ml. Each membrane was 
hybridized overnight at 65 °C in a separate bag. After hybridization, the membranes 
were washed twice (5 min each at RT) in 2X SSC, 0.1 % SDS, once 15 min at RT in .5x 
SSC, 0.1% SDS, and a final wash for 15 min at 65°C in 0.5X SSC, 0.01% SDS. 
Detection was carried out essentially as described, however, we found that instead of 
discarding the blocking reagent after the blocking step the antibody can be added directly 
(first pour out blocking reagent, add antibody, mix, then cover membranes). Once 
Lumi-Phos™ was added the membranes were exposed to X-Ray film (Fuji) for 5 to 50 
minutes. Films were scanned on a laser densitometer (Pharmacia LKB Ultroscan XL).
D. KSS ANALYSIS
1. Tissue Acquisition and Isolation of Brain mtDNA
Dr. W. W. Tourtelotte of the National Neurological Research Specimen Bank 
(NNRSB) kindly supplied brain samples. Tissue/fluid specimens obtained from the 
NNRSB, VAMC (VA Wadsworth Medical Center), Los Angeles, CA 90073, are 
sponsored by the National Institutes of Neurological Diseases and Stroke, National 
Institutes of Mental Health, National Multiple Sclerosis Society, Hereditary Disease 
Foundation, Comprehensive Epilepsy Program, Tourette Syndrome Association, Dystonia 
Medical Research Foundation, and Veterans Health Services and Research
26
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Figure 4
TOTAL DNA ISOLATION FORM PARAFFIN-EMBEDDED TISSUE 
Outline of total DNA isolation procedure used for paraffin embedded brain tissue.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Cut off excess paraffin while sample is on block and collect 8 micron slices using a 
microtome I
Place slices in . 5 ml microfuge tube
1
Add 400 fil 100% ethanol, place at RT for 5 minutes
i
Centrifuge 5 minutes, decant ethanol
1
Air dry pellet at RT or in heat block at 50°C
1
Add 150 n\ sterile water and resuspend tissue
1
Incubate tissue at 95 °C for 10 minutes 
Centrifuge 5 minutes, collect pellet
1
Digest tissue using 200 /xg/ml proteinase K in 200 fil digestion buffer (50 mM Tris, 1 
mM EDTA, .5% Tween 20)
1
Incubate at 55 °C for 3 hours
1
Heat inactivate proteinase K at 90° C for 10 minutes
I
Spin 5 minutes, collect supernatant for PCR
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Administration, and Department of Veterans Affairs (Appendix A). Dr. Peter Davies 
of the Department of Pathology at Albert Einstein College of Medicine also provided 
frozen brain samples (Appendix B). Total DNA enriched for mtDNA was isolated from 
frozen autopsy brain samples as described for rat brains. Paraffin embedded brain tissue 
was obtained from Dr. William Rosenblum of the Department of Pathology at the 
Medical College of Virginia. Details of the paraffin DNA isolation are described in Fig.
4. Briefly, 8 micron paraffin slices were dissolved using xylene, digested with proteinase 
K then ethanol precipitated.
2. PCR Conditions and Primer Synthesis
Oligonucleotides, synthesized (Biosearch Cyclone Plus DNA Synthesizer) using 
phosphoramidite precursors, were column purified (Milligen Oligopak). Primer 
sequences were derived from the Cambridge human mitochondrial genome sequence (89) 
and were selected using Primer Designer Version 1.01. To amplify normal and deleted 
mtDNA PCR was performed (Bamstead Thermolyne Temp-Tronic Cycler) using a 
multiplex buffer (90). The 50 id cocktail contained 1.5 mM each dNTP, 16.6 mM 
(NH4)2 S04, 67 mM Tris-HCL, 6.7 mM MgCl2, 10 mM j8 mercaptoethanol, 170 /xg/ml 
BSA, 6.8 nM EDTA, 20 pm each primer, 2.0 U  Taq polymerase (Perkin Elmer Cetus) 
and 5 fd DMSO. Cycle parameters were 30 s @ 94°C, 30 s @ 53°C, and a 1 min 
extension @ 65°C. Primer sequences were as follows:
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D, Left: CCATCTTTGCAGGCACACTCATC (np 4504-4526)
Ej Right: ATCCACCTCAACTGCCTGCTATG (np 4955-4977)
J! Left: AGCAAACCACAGTTTCATGCCCA (np 8188-8210)
Km Right: TAATGTTAGTAAGGGTGGGGAAG (np 13644-13666)
Li, Left: TTCTCATAATCGCCCACGGG (np 11700-11719)
U  Right: GTCGTAAGCCTCTGTTGTCAGAT (ip 12172-12194)
3. Serial Dilution PCR
The serial dilution PCR method of Corral-Debrinski et al. (91) was used for 
quantifying deleted mtDNA. Total DNA was diluted in two ranges; one for deleted 
mtDNA amplification and one for wild type mtDNA amplification. Primers were 
synthesized (J rK J  that span the deleted junction. Amplification across the deletion 
breakpoints yields a 500 bp fragment representative of the 4977 bp deletion whereas wild 
type DNA yields a 5478 bp fragment. If a short polymerization step is used; only the 
deleted 500 bp fragment will be amplified. However, instead of comparing wild type 
(5478 bp) to deleted mtDNA (500 bp), the ratio is determined using amplification of a 
product having a size similar to the deleted fragment. Thus, primer set D1-E2 which 
yields a 473 bp fragment was selected to amplify total mtDNA since this region near the 
light strand origin of replication is not as susceptible to deletions. Samples were 
linearized with Bam HI (which does not cleave within the deleted area) prior to 
amplification. This was done in order to eliminate catenates of the mitochondrial genome 
which could alter access by primers. PCR products were electrophoresed on an 8%
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polyacrylamide gel and visualized by ethidium bromide staining and UV illumination. 
Photographs were taken using Polaroid type 55 film and negatives were scanned using 
a laser densitometer (Pharmacia Ultroscan XL).
4. Kinetic PCR
Kinetic PCR was performed as described by Ozawa et al. (92). For kinetic PCR 
the same principle applies as for serial dilution PCR; the intensity of deleted mtDNA 
amplification products is compared to undeleted mtDNA PCR products. For kinetic PCR 
however, a ratio is generated based on normal mtDNA only (not total mtDNA). Primer 
set Li,-L2 amplifies a 494 bp fragment that is internal to the KSS deletion area, thus this 
amplification reflects only normal mtDNA. Each reaction contained the same starting 
amount of mitochondrial enriched DNA (25 ng). Reaction tubes were removed from 10 
to 20 cycles for undeleted mtDNA (Lil-L2) and stopped from 22 to 32 cycles for deleted 
mtDNA (Jl-KM). [a-32P] dATP (7 Kbq; 800 Ci/mM) was added to each PCR tube. 
Products were separated by gel electrophoresis, the gel was dried and radioactivity was 
determined by phosphorimaging (Molecular Dynamics Phosphorlmager SF).
E. MINOR REGION ANALYSIS
1. PCR Conditions
Primer set Br F2 (1257-5720) was used to amplify the minor region of brain mtDNA 
using the following cycling parameters: 30 s @ 94°C, 30 s @ 58°C and either 1 min
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(short program) or 5 min (long program) @ 65°C. A standard PCRbuffer (90) (50 mM 
Tris-HCl, pH 8.4, 50 mM KC1, 1.5 mM MgCl2. .01 % gelatin) containing 200 /xM each 
dNTP, and 0.5 ( j l M  each primer (final conc.) was used in a 100 /xl reaction volume. 
Primer sequences were as follows:
Bj: 5’GCCAGTTGATTAGGGTGCTT 3’ (np 1257-1276)
F2: 5’TATACCGCCATCTTCAGCAA 3’ (np 5700-5720)
2. Restriction Digestion and Dideoxv Sequencing
All digests for restriction mapping were carrried out at 37°C. Sanger dideoxy cycle 
sequencing (93) was performed using the finol kit (Promega). Primers were synthesized 
to give a sequence read length of 250 to 350 bp using 1.5 hr and 3.0 electrophoretic hr 
runs @ 65 W. Specific primers were end-labeled with T4PNK and [y-32P] ATP (3000 
Ci/mM). To obtain sequence data further from the primer, some electrophoretic 
separations were for 4 to 5 hours. Template was PCR amplified then purified with either 
Magic PCR Preps (Promega) or Prep-a-Gene DNA Purification kits (BioRad). The final 
jmol reaction volume was 6 X to which an equal amount of dye (95 % formamide, 0.25 % 
BPB, 0.25% XC) was added. The samples were denatured at 95 °C for 3 minutes and 
3 X was loaded on either 6 % or 8 % Instagels (8 M UTea), electrophoresed, transferred 
to 3M Whatman and exposed overnight without an intensifying screen.
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F. DIAGNOSTIC RESTRICTION ENZYME DIGESTION
1. Mutation Detection in Brain
Analysis for the MERRF8344, MET.AS3243, ND13397 and tRNAgl” 4336 mutations were 
primarily done in the same manner; the region of interest was PCR amplified followed 
by restriction enyme digestion in which case the presence of the mutation created a 
restriction site. Since these mutations are heteroplasmic containing both mutant and 
normal mtDNA, [a-32P] dATP was incorporated into the PCR products during 
amplification to increase detection of low amounts of heteroplasmy. Sequences for the 
MERRF mismatch primers were obtained from Siebel et al. (94). The remaining primer 
sequences were designed by Primer Design Version 1.01 and are based on the human 
mitochondrial sequence except for Tj which is derived from bovine mitochondrial DNA. 
MERj: 5’CCCCTCTAGAGCCCACTGTAAAGC (np 8282-8305)
MER2: 5’GGGGCATTTCACTGTAAAGAGGTGCCGG (np 8345-8372)
T,: 5 ’TACGACCTCGATGTTGGATCAGGAC (np 2980-3004)
B2: 5’CGATTAGAATGGGTACAATGAGG (np 3330-3352)
C,: 5’GCAATGGCATTCCTAATGCTTAC (np 3352-3375)
D2: 5’ACTTGATGGCAGCTTCTGTGGAA (np 4496-4506)
2. Mutation Detection in Lymphoblasts
Fifteen lymphoblast cultures from AD patients, unaffected spouses and age 
matched controls were supplied by Dr. P. Michael Conneally of the Department of
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Medical and Molecular Genetics at Indiana University, Alzheimer’s Disease Cell Bank 
(Appendix C). Cell lines were received in frozen ampules and were thawed one at a 
time in a 37°C water bath. Cells were grown in 5 % C02, 15 % FBS/RPMI 1640 media 
containing antibiotics and glutamine. Cultures were split every 2 to 3 days. DNA 
enriched for mtDNA was isolated as for small scale brain isolation (Fig 1.) from 
approximately 2 - 4 x 106 cells.
G. SINGLE STRAND CONFORMATION POLYMORPHISM ANALYSIS
1. SSCP-PCR Conditions
The COI, COII and COin subunits were screened using the mutation detection 
technique, single strand conformation polymorphism (SSCP) (95,96). Left and right 
primer sequences are listed below; primers with subscript 1 notation represent the light 
strand sequence and subscript 2 denotes the heavy strand.
COI,: (np 5900-5919) 5’ ACTGATGTTCGCCGACCGTT
H2: (np 6451-6473) 5’ GATTAGGACGGATCAGACGAAGA
I.: (np 6471-6492) 5’ ATCACAGCAGTCCTACTTCTCC
COI2: (np 7581-7600) 5’ CGCTGCATGTGCCATTAAGA
c o n ,: (np 7600-7620) 5’ GCAAGTAGGTCTACAAGACGC
I2: (np 8167-8189) 5’ CTCCACAGATTTCAGAGCATTGA
J,: (np 8188-8210) 5’ AGCAAACCACAGTTTCATGCCCA
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COE,: (np 8421-8438) 5’ GGGTGATGAGGAATAGTGT
COm,: (np 9186-9205) 5’ CTACCTGCACGACAACACAT
COm2: (np 10126-10145) 5’ GCCGTTGAGTTGTGGTAGTC
Complex IV genes were PCR amplified in separate tubes (Bamstead Thermolyne 
TempTronic Cycler) from brain mtDNA using a multiplex PCR buffer (1.5 mM each 
dNTP, 16.6 mM (NH4)2 S04) 67 mM Tris-HCl, 6.7 mM MgCl2, 10 mM 0- 
mercaptoethanol, 170 /xg/ml BSA, 6.8 fiM  EDTA, 20 pm each primer, 2.0 U Taq 
polymerase (Perkin Elmer Cetus) and 5 n 1 DMSO). Cycle parameters were: 30 sec @ 
94°C, 30s @ 53°C and a 2 min extension at 65°C.
The COI gene (5904-7444) was amplified using two primer sets: COI, -H2 and 
I, -COI2, the COII gene (7586-8262) using primer sets: COH, - 12 and J, -COII2i and 
COm (9207-9990) using COm, - COm2. The PCR-amplified regions were labeled by 
incorporating [a-32 P] dATP during amplification and restriction digested @ 37° C for 2 
hours to yield fragments of optimal size for SSCP (Table 2). The digestion products were 
heat denatured in 95% formamide, 20 mM EDTA and electrophoresed in a 0.5X MDE, 
10% glycerol-hydrolink gel (J.T.Baker) for 16 hours at 8 W then autoradiographed 
usually for 3 days with an intensifying screen. Sanger dideoxy cycle sequencing was 
performed as described above. Optimization of SSCP was done using the LHON cell 
line which was a generous gift of Douglas C. Wallace, Department of Genetics and 
Molecular Medicine, Emory University School of Medicine.
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Table 2
RESTRICTION DIGESTS USED TO OPTIMIZE SSCP MUTATION
DETECTION
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Amplified Region Restriction Enzyme Digest Size of Fragments*
COI:
C01,-Hj Hae m 233,213,127
Ir COI2 HpaQ, Xbal 354,236,162,160.117.100
1,-COl, HpaQ, PstI, Bgl 386,246,162,117.100.60,48
COD:
con.-ij Hae m 303,286
j,-con3i 250
com:
com.-com, SfaNl, Hhal, Hindi 236,194,185,157,131.56
comrcom2 Alul, Hhal, Hindi 370,264,194,131
1 Restriction enzyme generated DNA fragments are arranged in order of decreasing size not in 
order of position along the original PCR amplified region.
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2. Silver Staining
Silver staining was done according to the method of Anolles and Gresshoff (97). 
Acrylamide gels were fixed (1.5 mm thick, 15x18 cm) in 50 mis of 7.5% acetic acid 
for approximately 15 minutes. Gels were then washed in ultrapure water 3 times for 
about 4 - 6  minutes each. Silver impregnation was then accomplished by soaking gel in 
50 mis of 1.5g/L AgN03, 0.056% formaldehyde for about 45 minutes. After a brief 
rinse in sterile water, the gel was developed in 30g/L Na2C 03, 0.056% formaldehyde, 
400ug/L sodium thiosulfate. This solution should be between 8-10°C and image 
development took between 5 to 20 minutes. Image development was then stopped with 
cold (4°C) 7.5% acetic acid.
H. PC-12 ANALYSIS
I. Generation of rho zero (o°) cells
One flask of PC-12 (HGPRT) cells were obtained from Llyod A. Greene, 
Department of Pathology, Columbia University, New York, New York. Cells were trans­
ferred into 75 cm2 flasks that were pretreated with polylysine to aid cell adhesion. This 
was done according to the method o f Yavin et al. (98). lOOx poly lysine stock solution 
was diluted to lx  in lOmM Na2C 03. Phenol red was added, the pH was adjusted to 9.0 
to 9.3 (solution turns a deep purple) then filter sterilized. Polylysine was added to flasks
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for 30 min then removed, flasks remained at RT for another 30 min then were washed 
(2x with sterile water). Flasks were placed at 4°C until needed. Cells were routinely 
grown in 7% C 02, 5% fetal bovine serum/10% horse serum/RPMI 1640 media that 
contained antibiotics (25 units/ml penicillin, 25 /*g/ml streptomyocin), glucose (4500 
mg/L) and Fungizone (.5/zg/ml). To more accurately determine cell density prior to an 
experimental measurement, cell clumping was prevented by treatment with EGTA (99). 
PC-12 cells were removed from the flask surface by positive pressure, centrifuged to 
collect cells, then resuspended in 1 mM EGTA media. Cells were returned to flasks and 
remained in EGTA/RPMI media for six hours. After this treatment cells were collected 
in 50 ml conical tubes and washed in medium diluted 1:1 with sterile water (twice, 2800 
RPM, 5 min spins). After the last wash cells were forcefully resuspended in complete 
media and counted. The generation of p° cells was designed according to the method of 
King and Attardi (100) with modifications. Cells were cultured in EtBr at two different 
concentrations for 7 days (100 ng/ml and 200 ng/ml) at a density of 2 x 10s cells/ml in 
12 well plates, 1 ml/well. The EtBr concentrations were based on methods described by 
(101, 102,103,104). The EtBr concentration was then increased to 500 ng/ml and 1000 
ng/ml for an additional 11 days. One group of cells were supplemented with pyruvate 
(ImM/ml) and uridine (.05mg/ml) as follows:
EtBr Py Ur
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At 3 day intervals cells were assessed for viability and cell growth using trypan blue 
exclusion in triplicate. After counting, cells were centrifuged and cell pellets were 
frozen at -70°C until DNA isolation. At day 18 two sets of wells/experiment were 
counted and the third set of cells were expanded into 10 cm petri dishes. These cells are 
presently being maintained in 0, 100, and 200 ng/ml EtBr supplemented with pyruvate 
and uridine.
2. Southern Transfer and Chemiluminescent Detection
To assess mtDNA content of drug treated PC-12 cells, Southern hybridization 
was performed using chemiluminescent detection as described in part C, section 3.
I. BIOHAZARDOUS PRECAUTIONS AND USE OF HUMAN SUBJECTS
Lymphoblast cell lines obtained from the Alzheimer’s Disease Cell Bank are EBV 
transformed. Tissue culture was done in a Labconco Purifier Class II Safety Cabinet. 
All personnel involved in this project have been certified to handle radioisotopes. 
Vertebrate animal (rat) decapitation was carried out in the Department of Physiology by 
Troy Rhodes however, Dr. Frank Castora has animal welfare assurance #A3012-01. 
Pathological specimens are exempt from IRB review according to exemption H  
(exemption for autopsy samples).
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CHAPTER m . RESULTS
This study began when it was reported that deleted mtDNA had been linked not 
only to mitochondrial myopathies such as KSS, but also with the general aging process 
and with Parkinson’s Disease (PD). Previous studies have pointed out the similarities 
between AD and PD and have identified common features suggesting that AD and PD 
may be on a clinical spectrum. Therefore, we undertook a study of deleted mtDNA of 
AD patients in order to assess the involvement of mutant mtDNA in this degenerative 
disease. We obtained brain tissue and lymphoblast cultures from AD and neuro- 
pathologically normal individuals and began an investigation. As we progressed we 
realized that specific issues had to be resolved; this included the use of frozen 
postmortem tissue in the analysis as well as appropriate methods for studying deletions. 
Thus, the first section of this project addresses these issues. Afterward we assessed 
deleted mtDNA involvement. In phase II we looked at point mutations in the genome 
using RFLP analysis. Later, we turned towards recently developed mutation detection 
systems such as heteroduplex and SSCP to unmask point mutations that do not lie in 
restriction sites. After optimizing SSCP we applied this technique to mutation analysis 
in AD and aged patients. The final phase, the p° study, reflects a rather recent avenue 
that we embarked upon. Currently, it does not directly involve the study of AD mtDNA 
but it was designed with the intent of eventually using it for AD complementation studies
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and represents the first attempts at developing this unique neurological system.
A. STUDY OF MITOCHONDRIAL DELETIONS IN BRAIN
1. Integrity o f Brain Mitochondrial DNA during Postmortem Delay
The investigation of mtDNA isolated from brain autopsy tissue of human subjects 
has the potential for complications caused by tissue decay (autolysis). Samples are frozen 
at -70 °C immediately after autopsy yet variability existed between the time of death and 
subsequent time of freezing (postmortem delay). To address the question of whether any 
significant mtDNA degradation is induced during postmortem delay, a kinetic study was 
designed using rat brain tissue. Using a small scale isolation, total DNA enriched for 
mtDNA was purified without the need for extensive overnight CsCl gradient 
ultracentrifugations. Time points were taken for intact rat brains that remained at room 
temperature for 0, 6, 12, 24 and 30 hours. MtDNA was restriction digested with Bam 
HI or Xhol, then electrophoresed on an 8% agarose gel. To enhance detection of 
abnormal mtDNA, chemiluminescent Southern analysis was performed. Fig. 5, lanes 1 - 
5 shows a Bam HI digest of the isolated rat mtDNA which generates an 11226 bp and 
a 5072 bp fragment. From this initial blot one can see that the mtDNA appears to be 
intact even after 30 hours. However, there seems to be a large amount of undigested
40
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Figure 5
SOUTHERN ANALYSIS OF POSTMORTEM RAT BRAIN MtDNA
Southern blot of rat mtDNA digested with Bam H I. Bam HI generates two bands of 
11226 bp and 5072 bp. DNA was isolated from brain tissue that remained at room 
temperature for 0, 6, 12, 24 and 30 hours. In the origin of lanes 2 and 3 one can see 
undigested mtDNA. The DNA was probed with CsCl purified placental mtDNA.
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mtDNA near the origin for the 12 hr and 24 hr time points as seen in Fig. 5 lanes 2 and
3. This was probably due to a large amount of salt carry over during the ethanol 
precipitation step. This may have been due to an extended precipitation overnight at - 
20°C . Thus, samples were redigested in a larger volume of sterile water in order to 
decrease the salt concentration. Fig. 6 more clearly demonstrates that there was no 
gross deletions or insertions generated as a result of the brains remaining at RT for 30 
hours in either the Bam HI (lane 1) or the Xho I digest (lane 5). (Time point 6 for the 
Bam HI digest was accidentally lost after digestion). Additionally digestion appeared 
complete as evidenced by the lack of slow molecular weight products near the origin. 
However, upon extended film exposure of the blot shown in 6, numerous bands appeared 
in the Bam HI digest, Fig. 7, lanes 1 - 4 but not in the Xho I digest lanes 5 - 9 .  We 
believe that the appearance of bands in the Bam HI digest does not reflect degradation 
of mtDNA due to postmortem delay; instead it is most likely due to star activity of the 
enzyme. Star activity refers to the loss of specificity of restriction enzymes under 
conditions of high enzyme concentration, variation in pH or changes in salt 
concentration. Of these three factors the last seems the most probable and very likely. 
(Salt crystals were visible after precipitation). The loss of specificity for the Bam HI 
recognition site, GGATCC could result in four other sites which would produce 
numerous cuts in rat mtDNA. These four potential sites are as follows:
GGAT: 157 sites, GATCC: 15 sites, GGATC: 15 sites and ATCC: 157 sites. On the 
other hand the Xho I recognition site, CTCGAC does not lend itself to any 5 or 4 bp 
restriction sites in rat mtDNA. This explanation is supported by the extended exposures
42
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Figure 6
SOUTHERN ANALYSIS OF RAT MtDNA WITH BAM H I AND XHO I
Southern blot of rat digests with Bam HI ( lanes 1-4) and Xhol (lanes 5-10). Xhol 
linearizes rat mtDNA into a 16298 bp band. Bam HI generates an 11226 bp and 5072 
bp band. Hours at RT are indicated above the lanes.
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Figure 7
EXTENDED CHEMILUMINESCENT EXPOSURE OF RAT MtDNA
SOUTHERN BLOT
Extended exposure of the Southern blot shown in Fig. 6. Discrete minor bands appear 
in the Bam HI digests but not in the Xhol digests.
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and densitometric scans of the chemiluminescent Southern blots for the Bam HI and Xho 
I digests. If the mtDNA was indeed actually being degraded, then the extended Xho I 
exposure would have revealed other species of mtDNA similar to the extended exposure 
of the Bam HI digest. If, on the other hand, the enzymes were beginning to exhibit star 
activity, then the Bam HI digest should show an increased number of bands while the 
Xho 1 digest (which does not lend itself to star activity) would still only show one band 
(linearized mtDNA) upon extended exposure. This is the case as seen in Fig. 7 (lanes 5- 
9) where only 1 band was detected after the 30 min exposure.
Densitometric scanning was also done on the chemiluminescent Southern blots to 
determine whether there were other species of degraded mtDNA that was not evident 
upon visual examination. Fig. 8 shows the area scan peaks for the 12 hour timepoint. 
The 10 min exposure indicates that for both the Bam HI (A) and the Xho I digest (B) no 
intermediate size DNAs were produced. (The 1 % peak for the Bam HI digest is due to 
a spot on the film in this lane). The 30 min exposure similar to the actual blot indicates 
that for the Bam HI digest minor species of mtDNA are evident (C) whereas the Xho 
I digest (D) still shows only one peak representative of linearized mtDNA.
45
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Figure 8
DENSITOMETRIC SCANS OF RAT MtDNA SOUTHERN BLOTS
Densitometric scans of the Southern chemiluminescent blots of rat mtDNA isolated for 
studying effects of postmortem delay. (A) and (B) represent traces of the 12 hour 
timepoint lane seen in Fig. 6. (C) and (D) represent traces of the same lane for the 
extended exposure blot shown in Fig. 7.
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2. Comparison o f Quantitative Methods Used in Deletion Studies
Since our rat study on autolysis indicated, that even after having sat at room 
temperature for 30 hours no appreciable mtDNA degradation occurred, we proceeded to 
investigate the well characterized mtDNAA4977 (bp 8470- bp 13477) in AD brain. PCR 
primers that flank the deletion region were used to discern deleted from undeleted 
mtDNA. Although primers have been published that scan the deletion area, we used a 
left primer, ^  (8188) that was previously synthesized in the lab and prepared a new right 
primer KM2 (13666). The right primer was selected based on primer pair criteria 
described in the Methods. If the mtDNAM977 is not present, a 5.5 kb PCR product is 
generated whereas the deleted PCR product is only 500 bp (Fig. 9). A long extension 
time of 5 min was used to allow amplification of both deleted and undeleted mtDNA. 
As can be seen in Fig. 10 the samples seem to fall into three categories: one is composed 
almost entirely of deleted mtDNA; another has about a 50:50 distribution of deleted and 
normal mtDNA; and the third has a small amount of deleted DNA but a predominance 
of normal mtDNA (105). Since a large proportion of the mtDNAA4977 seemed to be 
present in some of the AD samples, we reasoned that the deleted mtDNA should easily 
be visible by Southern hybridization. For this analysis mtDNA from 9 AD samples was 
linearized with Bam HI; normal undeleted mtDNA is 16 kb long whereas the 
mtDNAM977 yields an 11 kb band. Southern analysis of these 9 AD samples did not 
reveal any 11 kb bands indicating that the high proportion of deleted mtDNA in Fig. 10 
was, perhaps, the result of preferential amplification of the smaller undeleted band during
47
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Figure 9
DIAGRAM DEPICTING PCR AMPLIFICATION ACROSS THE KSS
DELETION JUNCTION
Map depicting location of the Keams-Sayre Syndrome (KSS) deletion and PCR primers 
used to amplify across the junction breakpoints.
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Figure 10
DETECTION OF THE KSS DELETION IN AD AND AGED BRAIN
Agarose gel of PCR amplification of mtDNA from Ad patients using primers flanking 
the 5 kb deletion associated with KSS and aging. Lane a, marker, lane b - o, frozen Ad 
brain samples (note that many samples have the 500 bp fragment indicative of deleted 
mtDNA. Note also that a number of samples have a mixture of deleted and undeleted 
mtDNA); lane p, PCR amplification of human placental mtDNA; lane q, PCR 
amplification of HL60 mtDNA.
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long extension PCR. Thus, in order to better measure the KSS deletion we turned to two 
PCR-based methods for measuring deleted mtDNA, serial dilution PCR and kinetic PCR. 
As we began to work with both of these techniques we observed that these two methods 
were yielding disparate results. This was an important observation in light of the fact 
that in articles aimed at reviewing the role of mtDNA deletions in aging and 
neurodegenerative disease the percent of deleted mtDNA in different tissue types is 
compared from studies using different quantitative approaches (106,107). Thus we sought 
to determine how comparable the PCR-based methods are in their estimation of deleted 
mtDNA given the propensity for PCR amplification to vary due to cycle efficiency, 
structure of the template, the presence of tissue inhibitors, and primer requirements. We 
have compared the two most widely used techniques by determining the amount of the 
mtDNAA4977 in two regions of the brain from autopsy tissue of an individual with lung 
cancer (108).
Quantitation of deleted mtDNA by serial dilution PCR - We used a serial 
dilution PCR procedure to quantify the amount of deleted mtDNA in two regions of the 
brain from a patient with lung cancer (CA). The parietal cortex and the caudate were 
selected because these regions often show neuronal degeneration in neurodegenerative 
diseases such as Alzheimer’s Disease and Parkinson’s Disease. The primers D1-E2 
would be expected to amplify a 473 bp DNA fragment from total mtDNA (both wild type 
and deleted) in the sample while the primers Jl-Km would give a 500 bp PCR product 
amplified only from deleted mtDNA. Fig. 11 shows such PCR products generated using
50
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Figure 11
SERIAL DILUTION PCR GEL OF THE KSS DELETION IN A LUNG
CANCER PATIENT
Serial dilution PCR of the common deletion 5 kb deletion in parietal cortex from a lung 
cancer patient. Polyacrylamide gel of PCR products representing amplification of deleted 
mtDNA (500 bp) and total mtDNA from serial dilutions. MtDNA was diluted in two 
ranges, one for deleted mtDNA (.25 jmg - 976 pg) and another for undeleted mtDNA 
(.5 ng - 1.95 pg) amplification. Starting concentrations were determined by 
spectrophotometry at 260 nm.
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DNA samples from the parietal cortex. The left half of Fig. 11 shows a serial dilution 
of the 500 bp product decreasing as the amount of substrate DNA is reduced from 250 
ng to 976 pg. It can be seen that a significant amount of deleted mtDNA is detectable 
at all levels of input DNA examined. Similarly, as seen in the right half of Fig. 11, 
there is the expected decrease in the 473 bp PCR product amplified from total mtDNA 
as the amount of input DNA is reduced from 500 to 1.95 pg.
The ratio of deleted to wild type mtDNA was determined by densitometric 
measurement of the intensity of each DNA band and subsequent plotting of the optical 
density versus the log of weight of DNA in the reaction mix. The optical density was 
adjusted so that the area of each DNA band was normalized by the size of the DNA 
fragment. A typical result of this quantitation is shown in Fig. 12. In order to calculate 
the ratio of deleted mtDNA, the plots of deleted and wild type PCR products generated 
by Jl-Km and D1-E2, respectively, were examined to determine the logarithmic values 
on the x axis at which the optical densities of the deleted and undeleted PCR products 
were equivalent. To maintain accuracy using the serial dilution method it is important 
that an O.D. value is selected that is within the linear range of the density curve and has 
low standard deviation. For Fig. 12 an O.D. of 1.4 was used to determine the amount 
of deleted mtDNA (17.78 pg) and total mtDNA (12,590 pg). Thus, by serial dilution 
PCR methodology, in this patient’s parietal cortex there is a ratio of deleted mtDNA:total 
mtDNA of 0.0014 or a percentage of deleted mtDNA of 0.14%.
Table 3 shows the results of this analysis for the parietal cortex as well as the 
caudate region of this CA brain sample. Interestingly, the identical analysis of the
52
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Figure 12
OPTICAL DENSITY GRAPH OF SERIAL DILUTION PCR FOR
QUANTITATION
After visualization with ethidium bromide, negatives were scanned by laser densitometry 
to determine the area of each band. A plot of normalized optical density versus the log 
of the weight of DNA was generated for both primer sets. A ratio of deleted to 
undeleted mtDNA was determined by locating a unit of equal optical density for both 
plots, then comparing the DNA weights needed to yield such an O.D.
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Table 3
PERCENTAGE COMPARISON OF THE KSS DELETION AS DETERMINED 
BY KINETIC PCR AND SERIAL DILUTION PCR
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a. by optical density
b. by phosphorimaging
c. tissue analyzed in triplicate
caudate region showed that there was a 10-fold higher percentage of deleted mtDNA in 
the caudate of the CA brain than in the parietal cortex (1.41 vs 0.14%).
Quantitation of deleted mtDNA by kinetic PCR - The same CA brain sample 
was assessed for the amount of deleted mtDNA by another often used procedure - the 
kinetic PCR method. In this approach, PCR products were examined after variable 
cycles of reaction, usually ranging from 10 to 40 cycles depending on whether total or 
deleted DNA were to be detected. Fig. 13 shows that the 500 bp band of deleted mtDNA 
produced from primer Jl-Km is visible after 24 cycles and it increases in intensity up 
to 32 cycles. Similarly, to assess the amount of normal mtDNA, primers Lil-L2 were 
used to generate a 494 bp fragment, which is detectable at low cycle numbers due to the 
greater amount of normal mtDNA in these samples.
During the amplification reaction, radioactive dATP was included so the 
quantitation of these samples was obtained by phosphorimaging. A plot of log of pixel 
density versus cycle number was used to determine the ratio of deleted mtDNA to normal 
mtDNA (Fig. 14). Pixel density was normalized by the number of A’s present in each 
fragment. Extrapolation to zero cycles allows estimation of the ratio of wild type to 
deleted mtDNA in the starting material. For the parietal cortex sample seen in Fig. 14, 
this ratio is 0.001/0.0316227 indicating that the percentage of deleted mtDNA is 3.16%. 
A similar kinetic PCR analysis of the caudate yielded a value of 12.58% for deleted 
mtDNA. Thus, there is about a 4-fold higher amount of deleted mtDNA in the caudate 
than in the parietal cortex, as determined by kinetic PCR (Table 3).
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Figure 13
KINETIC PCR GEL OF THE KSS DELETION IN A LUNG CANCER
PATIENT
Kinetic PCR quantitation of the common deletion in parietal cortex from lung cancer 
patient. Polyacrylamide gel electrophoresis of PCR products generated by Lil-L2 (494 
bp fragment internal to KSS deletion, reflecting normal mtDNA) and Jl-KM (500 bp 
fragment from deleted mtDNA).
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Figure 14
RADIOACTIVITY GRAPH OF KINETIC PCR FOR QUANTITATION
The gel was dried at 60°C for 1 hr and radioactivity was quantified by phosphorimaging. 
A plot of normalized radioactivity versus the number of PCR cycles is used to calculate 
a regression line from normal and deleted mtDNA. Extrapolation to 0 cycles is used to 
determine the starting ratios of deleted to wild type mtDNA.
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For accurate kinetic PCR it is necessary to perform preliminary amplification to 
determine the linear range in which to work. For example, if the number of cycles 
selected is too high, the later PCR cycle products will be in a plateau region, and thus, 
the PCR products will be amplified to the same intensity. As seen in Fig. 15, from 32 
to 40 cycles there is no increase in amount of PCR product being amplified. Therefore, 
inclusion of data in this cycle range would skew the regression line leading to an 
overestimation of the percentage of deleted mtDNA. If, however, time points are taken 
from 22 to 32 cycles, a linear range of amplification can be achieved. In Fig. 16, PCR 
products were run on a polyacrylamide gel and bands scanned using laser densitometry 
to determine optical density. As can be seen, cycles 12 -18 for wild type and cycles 24 - 
30 for deleted mtDNA yield points in a linear phase of amplification.
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Figure 15
AGAROSE GEL OF PLATEAU EFFECT - KINETIC PCR
Plateau effect when cycle points for kinetic PCR are taken during the non-linear range 
of amplification. For kinetic PCR it is essential to empirically determine the linear range 
of amplification for deleted mtDNA. For time points 32 to 40, amplification using Jl- 
KM resulted in bands of equal intensity when stained by ethidium bromide.
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Figure 16
OPTICAL DENSITY PLOT DURING NON-LINEAR PHASE OF
AMPLIFICATION
As determined by scanning the negatives taken of the EtBr stained gel a plot of O.D. 
versus the number of cycles for the same sample indicates that a range of 22 to 32 cycles 
results in amplification in the linear range.



































3. Evaluation o f mtDNA*4977 in Alzheimers’s Brain versus Aged Individuals
Since serial dilution PCR seemed to be a more accurate method for measuring 
deleted mtDNA we proceeded to use this technique in our study of the KSS deletion in 
AD brain. Initially we used mtDNA that had been isolated from paraffin embedded 
tissue. While we could amplify mtDNA from these samples the amplification was often 
sporadic. Later, we received frozen brain tissue which yielded consistent positive PCR, 
thus, we continued our investigation with the frozen autopsy samples rather than the 
paraffin embedded tissue. We wanted to assess the difference in mtDNAA4977 in the 
hippocampus, an area predominantly affected in AD with plaques and tangles. However, 
tissue in this area was almost impossible to obtain from any of the brain banks. We were 
able to obtain tissue from the parietal cortex, caudate and temporal cortex; of these three 
regions the temporal cortex is most affected by plaques and tangles. Thus, mtDNA was 
prepared from the temporal cortex of 5 AD subjects with a median age of 69 yrs and 
from 5 control subjects with a median age of 68 yrs. All of the control brain samples 
were histologically normal whereas the AD brain tissue were all autopsy confirmed. The 
percentage of mtDNAA4977 was calculated as described in the previous serial dilution 
section. As can be seen in Table 4 the mean % mtDNAA4977 for the control group was 
.0053% while the AD group had a level of .0628%. This represents a 12 fold difference 
for the Alzheimer’s group. To determine statistical significance the mean % mtDNAA4977 
was compared using the student’s t test. Since the variance for the two groups was 
different, .008 (AD) vs .00003 (control) a separate t-test instead of a pooled t-test was
61
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Table 4
QUANTITATION OF THE KSS DELETION IN TEMPORAL CORTEX OF AD
AND AGED BRAINS





CASE # AGE % DELETED CASE # AGE % DELETED
1537 64 .0070 1569 61 .0079
1802 65 .2230 1413 67 .0014
694 68 .0141 1539 68 .0013
576 72 .0560 1903 70 .0141
1807 75 .0138 1846 73 .0016
Mean Age: 69 yrs Mean Age: 68 yrs
Mean % mtDNA4”7: 
.0628% +/-.041
Mean % mtDNA4977: 
.0053% +/- .003
s2 = .008 s2 = .00003
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performed. A t-value of 1.4 was obtained with a p =  0.116 for a one-tailed test and p 
= .223 for a two tailed test. For one AD case # 1802 the % mtDNA4977 is almost 10 
fold higher than the other samples in this group. If we treat this point as an outlier then 
the mean level of the KSS deletion in the AD group is .0027% which represents a four 
fold difference over the control group level of .0053 %. The four fold difference is not 
statistically significant at the .05 to .10 level. The t values and variances were 
calculated using formulas described by Munro, Visintainer and Page (109) and 
QuattroPro Version 5.0. Each sample was analyzed in duplicate. No conclusions 
could be made for the parietal cortex and caudate since the AD samples for these regions 
are at minimum 10 years older than the control group.
4. Minor Region Analysis
Whereas most deletions such as the KSS deletion occur between the Hs and the 
Ls origins of replication in the "hotspot" region of the genome minor region deletions 
can occur. Wei et al. detected a 3 kb deletion (mtDNA^610) in aged skeletal muscle in 
the minor region at a CCCC junction (110). The authors noted that this deletion had not 
been detected in other tissues examined. This is an unusual observation because most 
mtDNA deletions associated with mitochondrial myopathies accumulate as we age in a 
number of tissues with the exception of hematopoietic tissue due to its high turnover rate. 
Thus we wanted to determine first whether this deletion occurred in aged brain and 
second whether there any unique minor region deletions associated with AD. To detect
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Figure 17
DIAGRAM OF PCR AMPLIFICATION OF MtDNA3610 MINOR REGION
DELETION
Map depicting location of the skeletal muscle deletion in the minor region of the genome. 
The PCR primer pair used to detect this mutation is shown as well.




I 3810 bp excised I
Deleted h m b m b h m i e  853bp
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the mtDNA*3510 PCR amplification across the deletion junction (bp 1837-bp 5447) 
similar to the KSS amplification was performed using primer pair B, (bp 1257)- F2 (bp 
5720). The presence of the mtDNAA3610 should generate an 853 bp band as depicted in 
Fig. 17. However no bands migrating at 853 bp was detected in either the AD brain 
tissue or in any normal aged brain using a short (1 min) extension time for the PCR. 
Rather another smaller molecular weight band was observed that was migrating at 
approximately 600 bp (Fig 18A. lanes A, B) while a long extension time of 5 minutes 
amplified the expected undeleted product of 4463 bp (lanes C and D). We proceeded to 
restriction map the 600 bp band using the restriction enzymes Hindi, Kpn I, Pvu n, Xba 
I, Hha I and Hae HI. The 600 bp band was electroeluted and reamplified for restriction 
analysis. This was a necessary step due to the small amount of this deleted product 
visible on the acrylamide gel.
The cleavage sites and the respective cleavage products expected for the B,-F2 
4463 bp band are summarized in Table 5. Restriction digestion of the 600 bp deleted 
band (Fig. 18B) with Kpn I; lane B, Pvu Hr lane C, and Xba I; lane C, resulted in a 
single undigested band indicating that the 2573, 2650, 2953 recognition sites are missing 
(Table 5). The Hinc n  digest at first glance appears to generate only an uncut band but 
upon closer examination of the negative there is faint small molecular weight band of 
approximately 30 bp (Fig. 18C, lane A). This band was not readily detected in the 
Polaroid print since as a small band it does not bind a large amount of ethidium bromide. 
Thus, the Hinc II data indicates that the 2421, 3597 recognition sites are missing but not 
the 5691 site (Table 5). Taken together this information indicates that np 2421 ->  3592
65
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Table 5
EXPECTED RESTRICTION ENZYME DIGESTS - MINOR REGION RFLP
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Enzyme Cleavage Position Fragments Expected (bp)
Hinc n 2421, 3592,5691 2099,1171,1164,29
Kpn I 2573 1316,3047
Pvu n 2650 1393, 3050
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Figure 18
PAGE GEL OF RFLP ANALYSIS TO IDENTIFY A UNIQUE DELETION IN
THE MINOR REGION
Deletion analysis in the minor region of human brain mtDNA. Using primer pair Br F2 
(1257-5720) we detected a unique band of approximately 670 bp. (A) Lanes A and B, 
PCR using a 1 min extension on an AD and MS caudate sample; lanes B and C, the 
same samples using a long 5 min extension. The undeleted 4 kb band is visible as well 
as the 670 bp band, lane E, marker. (B) the 670 bp band was restriction mapped with 
Hinc II lane A; Kpn I, lane B; Pvu n, lane C; Xba I, lane D; Hha I, lane E; Hae 
HI, lane F. Lane G, markers.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
































Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
are missing, however np 5691 ->  np 5720 is present. Hha I digestion yields three 
bands, one at ~ 450 bp, another at 170 bp and a third at -  44 bp. Again here, the 44 
bp band was only visible in the negative (Fig. 18C, lane E). The Hha I digestion reveals 
that at least the np 1257-> 1301 and 1301-> 1472 are present since the expected bands 
from these sites are generated (Table 5). All other expected fragments are missing. 
There is also a 450 bp band present which is not expected given the Hha I cleavage sites. 
This could be due to partial digestion or it may be that a particular site is mutated. A 
point mutation at site 1768 could explain the presence of the 450 bp band in the 
following manner: if site 1768 is mutated and we include the 3.8 kb deletion, then a 443 
bp band would be generated as diagrammed below:
1472-----------1768------1893----------------------------------5698— 5720
1 1  
296 bp 125 bp deleted ~  3800 bp 22 bp
296 + 125 + 22 = 443 bp 
This would not necessarily be unexpected since the Hha I site, GCGC, is known to be 
a highly polymorphic site. The Hae HI digestion is expected to generate numerous bands 
however only two bands of ~ 460 bp and 250 bp are evident (lane F). The 460 bp band 
is most likely due to cleavage at np 5261 and 5720 which yields a 459 bp band. 
However, analysis of the 250 bp band is unclear since there are 6 possible cleavage sites 
that produce fragments around this size: 1257-1463 (207), 3607-3849 (242) and 4563- 
4848 (285). A summary of all of the restriction data reveals that np 2421-3592 is 
missing while np 1257-1472 and np 5691-5720 is not deleted.
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Before proceeding to sequencing of the deletion breakpoints we tested the 
specificity of the B,-F2 primer set since it was possible that the 600 bp product was 
actually the result of mispriming rather than a true deletion. Thus, we amplified the 
primer set under different conditions of magnesium concentration, an ion which is known 
to increase stringency of the reaction. The addition of MgCl2 to a final concentration of 
1 mM greatly enhanced amplification (Fig. 19A laneA ) whereas 3 - 9  mM inhibited 
amplification (lanes B,C and D). When AD and aged brain tissue was amplified with 
1 mM MgCl2 to increase primer specificity the 600 bp fragment was still evident (Fig. 
19B lanes A-F). Additionally, it seemed that even with the short extension time of 1 min 
the undeleted 4463 bp band was also amplified in some of the samples (lanes A and C). 
Since the 600 bp band seemed to indicate a true deletion product we proceeded to 
sequence the deletion breakpoints. As restriction mapping data indicated that np 1257- 
1472 was intact we synthesized left primers at 1488,, 1702,, and 1941,. The 1488, and 
1702, primers gave readable sequence data whereas the 1941, lanes were blank as if the 
primer had no complementary site to which to anneal. According to the read data the 
deletion spans 1893-5698 or 1899-5703 (mtDNA*3800*. A "GCTAAG" motif was found 
to bracket the deletion breakpoints. Unfortunately closer investigation of the 
"GCTAAG" indicated that the F2 left primer was indeed misannealing. As seen in Fig. 
20 the F2 primer does have the potential for forming 11 Watson-Crick bonds around np 
1900. After a few rounds of PCR this primer sequence generates a new template in this 
region such that sequencing comparison to the Cambridge mitochondrial sequence would 
appear as if a jump to np 5700 had taken place.
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Figure 19
MgCL SENSITIVITY OF B,-F2 PRIMER SET
Effect of MgCl2 concentration on primer pair Br F2 PCR reaction. (A) Amplification 
with placental mtDNA, lane A; 1 mM, lane B; 3 mM lane C; 9 mM, lane D; marker. 
(B) Amplification on control and AD brain tissue, lanes A through F using 1 mM 
MgCl2.
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Figure 20
SCHEMATIC OF MISPRIMING BY F2 RIGHT PRIMER
Region of mitochondrial genome that depicts mispriming by right primer F2. F2 can 
hybridize to its exact complementary sequence at 5720 as well as base pairing incorrectly 
around nucleotide position (np) 1900.




“  (mispriming b y  FZ)
B1
I1257 1914
I............................................ ...... .....  IJ________________________iGCTAAG; CACCCTAACAACTGGC____
9 1  (new  tem plate region}
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Our investigation of the presence of deletions in the hotspot region of mtDNA 
suggested a difference in the accumulation of a specific deletion that is elevated in the 
temporal cortex of AD brain. However, we decided to pursue another avenue of research 
that we believed would better lead to understanding mitochondrial abnormalities in AD. 
This is not to say that the deletion studies should not be continued. However, numerous 
other groups had started to look at the level of the KSS deletion in AD brain 
(111,112,113). Additionally, we reasoned that while the accumulation of specific 
deletion would have implications on energy metabolism in the brain of AD patients, the 
deletion measurements have been in general a very small percentage of the normal 
mtDNA, usually less than 1%. When the disease termed KSS is actually diagnosed, 
over 50% of the mtDNA has to be deleted in order for dysfunction to be manifested. 
Corral-Debrinski et al. have documented the greatest amount of the KSS deletion in AD 
brain approximately 10% (111). However, such a large percentage should be be easily 
visible on a Southern blot - thus, how accurate this measurement is may be difficult to 
assess until the Southern analysis supports these elevated percentages. Additionally, the 
KSS deletion deletes a number of subunits and complexes (part of ATPase 8, all of 
ATPase 6, COHI, ND3, ND4L, ND4 and part of ND5); thus, one should expect to see 
a generalized systemic defect in all of the OXPHOS complexes not necessarily only 
Complex IV. Therefore, for these reasons, we proceeded to analyze AD brain tissue for 
specific point mutations that could explain some of the specific respiratory chain 
deficiencies and physical symptoms in AD. We wished to determine whether the 
muscular deficits such as myoclonus, rigidity and seizures seen in Alzheimer’s
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patients were linked to mtDNA mutations that are known to cause muscle wasting such 
as that seen in the mitochondrial myopathies MERRF and MELAS. Additionally, we 
screened for two mtDNA mutations that occur in an elevated frequency in AD and 
Parkinson’s Disease (PD) individuals.
C. KNOWN MUTATION ANALYSIS - MERRF, MELAS AND AD-ASSOCIATED
MERRF is the result of an A ->  G transition in tRNAly“ at np 8344. This 
mutation is detected using mismatch PCR which creates a Nae I restriction site in 
positive individuals. A 90 bp fragment was amplified using MER, - MER2 (8282-8372) 
which is cleaved into a 64 and 26 bp fragment if the mutation is present. (Fig. 21 A). 
[a-32P] dATP was incorporated during amplification. Since the MERRF mutation is 
heteroplasmic, staining of acrylamide gels with ethidium bromide would not be sensitive 
enough to detect a small percentage of mutant mtDNA. Thus, gels were dried then 
exposed to autoradiography film. With this increased sensitivity however, there was still 
no evidence of the MERRF mutation in these samples. (Table 6).
The primary mtDNA mutation associated with MELAS is an A- > G transition at 
np 3243 in tRNAlcu. This mutation can be detected by either the creation of a Hae m  
or an Apa I site (Fig. 21B). A 372 bp fragment using primer set T,-B2 (2980-3352) was 
PCR amplified. With Apa I the 372 bp fragment is cleaved into 263bp and a 109 bp 
fragments if the A - > G transition is present whereas Hae HI digestion cleaves a 169 bp
73
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Figure 21
DIAGNOSTIC RESTRICTION ENZYMES USED TO IDENTIFY THE MERRF, 
MELAS, tRNA8*” AND ND1 MUTATIONS
Diagnostic restriction enzyme digestion used to detect the MERRF, MELAS, AD-ND1 
and AD-tRNAgln mutations. (A) The MERRF A- > G substitution at np 8344 is detected 
by mismatch PCR, if the mutation is present a Nae I site is created. (B) The MELAS A- 
> G substitution at np 3243 creates an Apa I site. (C) The AD-ND1 A- > G transition at 
np 3397 creates and Rsa I site whereas the AD associated tRNAgln change at np 4336 (D) 
generates a new Ava n  site.
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Table 6
SUMMARY - MERRF, MELAS AND AD ASSOCIATED MUTATIONS
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fragment into a 72 and 97 bp fragments. As with the MERRF analysis, extended 
exposure of the polyacrylamide gels did not reveal any samples that carried this mutation. 
(Table 6). For MELAS we did not continue our analysis on more than 9 AD patients 
since at this time reports of four other AD associated mtDNA mutations surfaced; one 
in the tRNAgln at bp 4336, in the NADH Dehydrogenase subunit I gene (ND13397), in 
NADH Dehydrogenase subunit 2 gene (ND45460) and one in the 16S rRNA at bp 3196. 
We did not screen for ND5460 (114) since one report was subsequently published stating 
that this variant was not detected in 15 AD patients examined (115) nor did we screen 
for 16S rRNA3196 since this variant was found to be heteroplasmic in an AD patient but 
homoplasmic in a control.
Instead we investigated AD brain mtDNA for the tRNAgln (np 4329 - 4400) 
mutation that has been reported in as many as 3.2% of the cases examined (5% in 
patients exhibiting both pathology of AD and PD), and for the ND1 gene (np 3307 - 
4262) mutation. The ND13397 mutation was detected using diagnostic restriction enzyme 
analysis where an Rsa I site is created if the A - > G substitution is present. A 1292 bp 
fragment was amplified with primers C,-D2 (3352-4644). Rsa I digestion yields a 1113 
bp and 179 bp fragment unless the mutation is present in which case the 1113 bp 
fragment is cleaved into a 1068 and 45 bp fragment (Fig. 21C). For the tRNAgln4336 
mutation the same primer set C, - D2 was used. In this case if the A- > G mutation is 
present an Ava II site is created resulting in a 984 and a 308 bp fragment (Fig. 21D). 
As can be seen in Fig. 22A one of our AD patients carried this variant which is near the 
Ti/'C stem of this tRNA (Fig. 22B). We additionally screened lymphoblast DNA from
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Figure 22
AVA H DIGEST DEMONSTRATING THE tRNA**"4336 VARIANT IN AN AD
PATIENT
Detection of the tRNAEln4336 mutation in the temporal cortex of AD patient #1802. (A) 
Agarose gel indicating creation of Ava II site by mutation. Region was amplified with 
Cr D2 which yields a 1292 bp band. If the T- >  C mutation is present a 984 and a 308 bp 
band is generated. (B) tRNA region affected by mutation (Shoffner et al. 1994).





^ 3 | a 4, c
E - 0
H* HU - O
3  • o  
u —u
<—3
< U U U < 5 U U 3 U
o
03033 — o





O o o - U
3— <
u - u  




0 < C « t <  p  
=>3
CM
O ) T f 0 0








Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5 AD patients for the tRNAgta4336 mutation and did not find this alteration. We did not 
include this information in Table 6, however, because only one of these patients was 
actually biopsy confirmed. Results of the ND13397 and the tRNAgln4336 mutations are 
summarized in Table 6.
The ND1 and tRNAgIn variants were detected by Shoffner et al. using RFLP 
analysis. The entire mitochondrial genome was screened by RFLP yet out of the four 
mutations identified by this group, three of them were focused in one specific region of 
the genome (np 3100 ->  np 4400). We wanted to determine whether other mutations 
were present in this area that were missed by RFLP analysis. We used PCR-SSCP to 
screen this region for additional changes. AD and control samples were amplified with 
C,-D2 digested with Ecor RI and Alu I which generate then run on a 10% glycerol SSCP 
gel. Polymorphisms were detected in 9 samples, 8 AD and 1 control. Sequencing 
analysis revealed this was due to 4 different mutations; one a G- > A change at np 3421 
which by itself does not alter the val residue, however, a second G->T mutation in this 
same AD patient at np 3423 alters the val to ile. The change at 3423 has been detected 
by other groups (116,117,118) while 3421 is a new variant. The third A -> G 
substitution at np 3480 is a silent change in lys while the A- >  G mutation at np 3843 
maintains a trp residue. These variants have been identified by Howell (116) and 
Masucci (119) respectively. Sequence variants for this region are summarized in Table 
7.
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Table 7
MtDNA POLYMORPHISMS IN THE ND1 GENE
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C. CYTOCHROME C OXIDASE (COMPLEX IV) ANALYSIS
After analyzing AD brain tissue for previously characterized mtDNA mutations, 
we focused our investigation on Complex IV (Cytochrome C Oxidase) of the electron 
transport chain. This was due to the number of studies that indicated there was a 
cytochrome c oxidase deficiency in AD platelets and in AD brain tissue. Furthermore, 
a reduction in message levels for mitochondrially encoded subunits I and in of the 
thirteen subunit Complex IV protein was found. We decided to first determine whether 
there were any deletions or insertions in the COX I, COX n  or COX HI genes using 
PCR amplification across the respective areas. Later we turned to an investigation of 
point mutations that may exist and for this analysis we used the mutation detection 
technique SSCP.
1. Deletion analysis o f  cytochrome c oxidase subunits I, I I  and III
To determine whether deletions or insertions were present in CO I, II and HI of 
Alzheimer’s patients, PCR amplification was performed on four brain regions (three 
regions normally affected by AD, hippocampus, parietal cortex, temporal cortex and one 
non-affected area, caudate). For a number of samples tissue was available from the 
parietal cortex, temporal cortex and caudate but unavailable from the hippocampus. 
DNA enriched for mtDNA (250 ng) was PCR amplified using overlapping primer sets 
to each of the three mtDNA-encoded subunits of cytochrome c oxidase (Fig. 23). If a
80
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Figure 23
PRIMER PAIRS USED TO SCREEN COX SUBUNITS I, H AND m  FOR 
INSERTIONS AND/OR DELETIONS
Depiction of primers used to screen cytochrome c oxidase genes I, n  and n  for 
mitochondrial DNA deletions and insertions.
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Figure 24
AGARSOE GEL OF PCR AMPLIFICATION ACROSS COX I, H AND m
Agarose gel of PCR deletion analysis of cytochrome c oxidase from four regions of the 
brain in Alzheimer patients. The COI primer set amplifies an undeleted fragment of 
1700 bp (a. lanes 1-4), COE, an 838 bp fragment (b. lanes 1 - 6 )  and CODI a 959 bp 
fragment (b. lanes 7 - 12). M, marker.









0 >  COm eo o> co




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
deletion was present, then a gel shift caused by a smaller, faster migrating PCR 
fragment would be evident, while an insertion would result in a band with retarded 
migration. Ten microliters of the PCR reaction were electrophoresed on a 1 % agarose 
gel and visualized by ethidium bromide staining. No macrodeletions or insertions were 
detected by PCR using the COI, - COI2 (Fig. 24A lanes 1 -4 ) ,  the COE, -COII2i (Fig. 
24B lanes 1 - 6) or COIII, - COm2 (Fig. 24B lanes 7 - 12) primer sets.
2. Identification o f  Polymorphisms In COX 7, I I  and II I  Using SSCP
Since by our analysis the mtDNA-encoded subunits COI, COE or COIE 
contained no large deletions or insertions that could account for abnormal cytochrome 
c oxidase activity, we screened Alzheimer brain tissue for point mutations using single 
strand conformation polymorphism (SSCP). SSCP can detect point mutations in single 
stranded DNA due to conformational changes induced by a single base change (Fig. 25). 
We screened a total of 24 different AD patients and a total of 16 control individuals 
showing no evidence of abnormal brain pathology. Information regarding sex and age 
of the patient samples is summarized in Table 8. In some cases, however, tissue was not 
available from all four brain regions. The COI, COE and COIE genes were PCR 
amplified from AD and control brain and restriction digested to yield optimal size 
fragments for SSCP (-3 5 0  bp see Methods). The COI gene (5904-7444) was amplified 
using two primer sets: COI, -H2 and I, -COI2, the COE gene (7586-8262) using primer 
sets: COE, - 12 and J, -COE2i and COEI (9207-9990) using COIE, - COEI2. Fragments
83
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Figure 25
SCHEMATIC DIAGRAM OF SSCP ANALYSIS 
Principle of single strand conformation polymoiphism (SSCP) used for mutation 
detection. DNA region of interest is PCR amplified to yield double stranded DNA which 
is denatured then run on a polyacrylamide or vinyl-based gel. Single strands as they 
migrate through the gel take on unique conformations based on primary sequence. Single 
strands that are identical except for a point mutation would induce one band to migrate 
to an altered position in the gel.
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Figure 26
SSCP-GLYCEROL GEL OF THE LHON 11778 MUTATION
SSCP analysis of the tRNAIeu 11778 mtDNA mutation associated with Leber’s Hereditary 
Optic Neuropathy (LHON). 250 ng of total genomic DNA isolated from cultured LHON 
lymphoblasts and 10 ng purified human placental mtDNA was PCR amplified with L r L^ 
(np 11490-12194). Products were visualized by incorporating radiolabeled dCTP during 
the PCR. Following restriction digestion with Hinf I samples were loaded on hydrolink 
gels. Panel A (0% glycerol): lane 1; LHON undenatured, lane; 2 LHON denatured, lane 
3; control denatured, lane 4; control undenatured. The 143 bp band carries the LHON 
mutation. Panel B (10% glycerol), 143 band was electroeluted, lane 1; LHON 
undenatured, lane 2; LHON denatured, lane 3; control undenatured, lane 4; control 
undenatured.
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Table 8
AGE AND SEX DATA FOR BRAIN TISSUE USED IN COX I,II AND m  SSCP
MUTATION DETECTION
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Patients: n = 24
sex: 12 6 12 9
age range: 60-92 yrs, mean 77
Controls: n = 16
sex: 14 6 2 9 
__________ age range: 21-72 yrs, mean S3
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dATP during amplification. SSCP-PCR products were run on a 10% glycerol hydrolink 
gel; this percentage gel was determined to give a reproducible SSCP signature when 
tested on mtDNA from cultured cells containing the tRNAleu A ->G 11778 mutation 
associated with the mitochondrial myopathy Leber’s Hereditary Optic Neuropathy 
(LHON) (45). The LHON region was amplified with primer set L^I^ (11490-12194) 
which yields a 704 bp fragment. Control and LHON PCR products were then digested 
with Alu I which generates a 307, 143, 105 and 8 6  bp band. The 143 bp band which 
harbors the mutation was electroeluted then ran under different SSCP conditions. Fig. 
26 indicates that the LHON SSCP polymorphism was not detected in a 0% glycerol gel 
as seen in lanes 2 and 4 (A) versus lanes 2 and 4 (B). Thirty two polymorphisms were 
detected, 9 in COI (7 AD, 0 control), 6  in COE (3 AD, 3 control) and 17 in COHI (11 
AD, 6  control). If one normalizes for the number of bases in each subunit and calculates 
the frequency of substitution based on the number of unique mutations, then COI is the 
least polymorphic subunit (5.2 x 10'3 changes/base; 8  nucleotide changes/1540 bp) while 
COHI is the most polymorphic (1.0 x 10'2 changes/base; 8  nucleotide changes/783 bp). 
As can be seen in Table 9A and B, dideoxy cycle sequencing confirmed the presence of 
point mutations in all but three cases, COHI AD# 1546, 1647, and 1977. Given the fact 
that some of the polymorphisms are the same nucleotide change although in different 
samples, 16 of the Complex IV mutations are new normal variants of the mitochondrial 
genome whereas 5 of the mutations have been previously identified as natural 
polymoiphisms (118,120,121,122). There are a total of 17 transitions and 2 
transversions. Three of the mutations are missense mutations that occur in COHI; the
87
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 9A
MtDNA VARIANTS IDENTIFIED IN COX I, II AND m
Seqeunce variants identified in AD and control tissue by SSCP in Complex IV, subunits 
I, II and HI. * previously reported variant, CA, cancer, BP, bronchial pneumonia, CHF, 
cardiac heart failure, MI, myocardial infarction. (+ ) indicates a distinct SSCP signature 
was detected.























































G->C 9559 arg- >pro
T->C 9698 leu









G->C 9559 arg- >  pro
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Table 9B
MtDNA VARIANTS IDENTIFIED IN INTERGENIC REGIONS OF COX I, II
AND m
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Case Diagnosis SSCP Mutation Position Region
1977 AD (+) C->T 7476 tRNA“r
1341 NC (+) 9 bp del start 8280 CO^/tRNAly,
3988 AD ND C-> A 8282 COn/tRNAly‘
485 MS (+) T->C 10034 tRNA‘ly
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first mutation at bp 9477 changes valine to isoleucine (control). The Val- > lie change has 
previously been published by Marzuki et al. (118) and is considered to be a fairly 
common nonsynonymous substitution in mtDNA (123). The second amino acid change 
at bp 9559 changes argine to proline (AD). The G ->C  arg9559 transversion which was 
previously published by Wallace in an individual with LHON is present in a number of 
our brain samples (45). We detected this variant in 1 normal control, in 2 Alzheimer’s 
brains and in placental mtDNA. The Arg9559 mutation is considered to be an ethnic 
variant representative of Caucasian populations. However, in a recent paper aimed at 
determining the last common ancestor of Europeans, Japanese and Africans (123) the 
authors noted that in their sequence analysis they did not find the 9559 mutation. Their 
conclusion was that the 9559 mutation did not represent a true ethnic polymoiphism. 
However, as indicated above, we detected this transversion in a number of Caucasian 
individuals. The third missense mutation at bp 9861 is a new variant detected by SSCP 
in AD #1702 (Fig. 27A that alters a Phe - > Leu. The Phe at codon 219 is a moderately 
conserved residue, present in a humans, cow, whale and seal while Leu is found in rat, 
opossum and frog. (Fig. 27B). This variant was not observed in any of our control 
brain tissue nor has it previously been reported in a mitochondrial database consisting of 
over 60 references dating from 1983 - 1994 (124) nor in "The report o f the committee 
on human mitochondrial DNA" accessed on the Internet (125). The mutation appears to 
be homoplasmic by sequencing.
For control # 1640 we detected two additional silent mutations in COI at bp 7256, 
C- > T (Asn) and at bp 7274, C- > T (Giy) that were detected prior to SSCP analysis for
90
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Figure 27
CODON 219 PHE-> LEU CHANGE IN COX HI OF AN AD PATIENT
Identification of cytochrome c oxidase (COX) subunit HI T->C point mutation at np 
9861 in temporal cortex of an AD patient. (A) SSCP gel - region was amplified with 
COmr COm2 , digested with Sfa N l, Hha I and Hinc n. A unique SSCP signature is 
seen in the 236 bp band; lane C. Lanes A, B and D represent the normal pattern. (B) 
Mutation creates a phe- > leu missense mutation in the carboxy terminus of COX HI.
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that region and are included in Table 9A. Additionally we detected four other mutations 
in tRNA’s or small intergenic regions that separate COX I, II and HI and thus are not 
included in Table 9A. A 9 bp deletion was found in the only short intergenic region of 
the genome between the COE and tRNAlys gene. The 9 bp deletion is considered to be 
an ethnic polymorphism present in Native Americans (126). The G- > A mutation at 7476 
is moderately conserved (rat, human, frog) and has been reported in other samples 
(127,128) as well as in a patient with Rett Syndrome (129). The Hs transcript for this 
region does not code for a mature tRNA, however, the light strand transcript codes for 
tRNAUCNscr. The tRNAgly mutation occurs within the stem structure that connects the 
anticodon domain (124, Manfredi, Unpublished). All of these mutations are summarized 
in Table 9B.
Aberrant SSCP signatures were present in all brain regions of a particular sample 
and by SSCP appear to be homoplasmic mutations. As can be seen in Fig. 28A, a point 
mutation in AD #3988 leads to the same SSCP pattern in the parietal cortex and caudate 
of this patient (lanes 1 and 7). Lanes 2 - 6 ,  and lane 8  are AD samples with the wild 
type SSCP signature, and lanes 10 and 11 are normal samples with the wild type pattern. 
This aberrant SSCP pattern was determined by dideoxy cycle sequencing (Fig. 28C) to 
be due to a T- > C transition at bp 9899 in subunit CO m  that results in a silent mutation 
in histidine. Likewise, as seen in Fig. 28B, AD #1573 showed the exact same SSCP 
signature and similarly had the 9899 variant.
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Figure 28
SSCP DETECTION OF THE 9899 VARIANT IN COX HI
10% Hydrolink-MDE gel demonstrating single strand conformation polymorphisms in 
the COHI gene of Alzheimer’s brain tissue. (A) The COHI gene was amplified with 
COmr COm2 (9186-10,145) and digested to yield fragments of 236 bp, 194 bp, 185 bp, 
157bp, 131 bp and 56 bp. Samples were denatured, loaded and electrophoresed for 17 
to 20 hrs at 6 W. A unique SSCP signature was detected in the 236 bp band in the 
parietal cortex (lane 1) and caudate (lane 7) of AD #3988. Lanes 2-6, 10, and 11 
represent the wild type pattern. The sample in lane 9 did not amplify. (B) In the parietal 
cortex of AD# 1573 the same pattern was generated for the denatured 236 bp band. (C) 
Upon sequencing this shift was determined to be due to a silent T->C mutation at bp 
9899.
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Additionally for one MS patient we detected what appeared to be an insertion in 
the COHI gene. Hinf I digestion of the COHIj-COIIIj PCR product yields a 562 bp and 
a 392 bp fragment. As can be seen in Fig. 29A, after Hinf 1 digestion the 567 bp 
double stranded DNA band for MS# 1401 had retarded migration on a non-denaturing 
poly- acrylamide gel compared to other Hinf I digested samples. The 567 bp band which 
spans np 9186-9753 was sequenced with read data obtained from np 9100-9800, yet, no 
insertions were detected that would lead to a slower moving band. Instead, the only 
change detected was a G - >  A substitution (B) at np 9433 that converts Val- > lie. Since 
it was possible that due to band compression we were not detecting a small insertion we 
ran the digested products on a denaturing gel. If an insertion was truly present then 
fragment retardation would still be present on the denaturing gel. However upon 
electrophoresis in an 8  M urea gel the aberrant migratory pattern for the 567 bp fragment 
disappeared (C). Since this was a single stranded DNA gel to increase detection we 
performed silver staining since EtBr does not intercalate as well in single strands. This 
indicates that the reptated pattern observed initially was not actually due to an insertion 
rather it was due to a conformational shift in double stranded DNA. To further support 
this idea the entire COHI gene (9207-9990) for MS#1401 was sequenced (read data 91 GO- 
9994) but no insertions were detected. Since the only mutation detected in this region 
was the G -> A substitution, we believe that the mutation is creating a (dA dT) tract, a 
dinucleotide motif which has previously been shown to create the phenomenon known 
as bent or curved DNA when it is repeated every 10 or 11 base pairs which would be 
in phase with the pitch of the double helix. The abnormal migration is reduced if the
94
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Figure 29
ANOMALOUS MIGRATION OF DOUBLE STRANDED DNA
Anomalous migration of double stranded DNA due to a point mutation, (a) Agarose gel 
of COHI gene PCR amplified with COfflpCOn^, digested with Hinf I which generates 
a 567 and 392 bp band. Slower moving upper band is seen in MS sample 1401, lane B. 
Lanes A, C and D normal digests. Lanes E and F; 1401 digest mixed with control 
digests, (b) Sequence analysis showing only mutation, a transition, detected in 567 bp 
band, (c) Hinf I digests were denatured and run on an 8 M urea denaturing gel then silver 
stained to detect single and double strands. Lane A; 1401, lanes B and C; control. Upper 
band is undigested sample.
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repeat motif occurs every 9 or 12 base pairs (156,157). The next repeat does not 
necessarily have to contain the same number of A’s as the first. The G->A mutation 
creates a sequence that meets two requirements for bending; one is at least four adjacent 
A’s and second, the degree of curvature increases if a C is on the 5’ side and a T is on 
the 3’ side of the A tract. For this mutated region a C is on one side although a T is not 
on the other. Additionally the stretch of base pairs containing the G- > A mutation does 
not show a repeat of 9,10,11 Or 12 base pairs, thus, while the substitution creates an A 
tract that could lead to anomalous migration, it is lacking in other aspects of the model.
3. Evaluation o f  SSCP in Mutation Detection
While SSCP is widely used for mutation detection, there have been differing 
reports as to its efficacy. Earlier studies suggested that SSCP was 80% accurate in 
detecting known mutations (127) while other studies have determined the efficiency to 
be approximately 90% (128,129). One recent study reported that hydrolink MDE gels 
containing 10% glycerol are 6 8 % efficient (130) at mutation detection. Thus, we wanted 
an estimate of how effective this technique was in our screening analysis. To determine 
whether point mutations existed that were not detected by SSCP we sequenced 99 % of 
the COI and COE genes for three Alzheimer’s patients and 99% of the COHI gene for 
two patients to determine if there were any additional mutations. If data was combined 
for the three patients then 100% of all three subunits were sequenced (Table 10). 
Alzheimer brain tissues that showed multiple mutations by SSCP were selected
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Table 10
SSCP EFFICACY - SEQUENCING ANALYSIS
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COI: 5904-7444
Primer Position 3988 1816 1977
G, 5717 ND = not done ND 5780-6045







I, 6471 6523-6720 6505-6709 6501-6761





6 , 7009 7051-7220 7051-7164 7051-7220
7| 7186 7230-7482 7223-7460,70 7230-7482
COH: 7586-8262
Primer Position 3988 1816 1977
7186, 7186 7436-7664 ND 7436-7664




3. 8188 8238-8324 8241-8370 8238-8375
COm:920'r-9990
Primer Position 3988 1816 1977
K, 9070 9116-9307 ND see below
com, 9186 9209-9370 ND 9215-9545
9342, 9342 9441-9567 ND see above
9523, 9523 9586-9759 ND 9568-9800
9731, 9731 9776-9887 ND 9764-10000
9861-10091
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for dideoxy cycle sequencing analysis. We found no additional point mutations in COE 
or COin. In COI we detected two additional silent mutations. One was a C ->T  
mutation at bp 5915 in AD #1977 in PCR fragments that had not shown an altered SSCP 
pattern and a second silent mutation was detected at bp 7028 in AD #1977 and in AD 
#3988. AD #1977 did show a migrational shift using primer set I-COI (6471-7600). 
However, another mutation at bp 6524 was originally thought to cause the SSCP pattern. 
AD #3988 did not show a unique SSCP pattern using primer set I-COI. In some cases 
more than one base change was detected in a fragment having a conformational shift. 
Additionally, other investigators have noted that PCR-SSCP results in abnormal 
conformational patterns even when a base change is not present (134). We had three such 
cases where a SSCP signature did not result in a detectable point mutation, AD #1546, 
1647 and 1977. These band shifts were not extremely noticeable on the SSCP gel and 
may reflect subtle changes in migratory differences for these lanes.
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D. RHO ZERO STUDY
1. PC12(HGPRT~) Growth Characteristics in Ethidium Bromide
To determine whether an identified missense mtDNA mutations is indeed 
pathogenic in AD or, to determine whether mitochondrial DNA defects in general lead 
to OXPHOS defecits in AD could be addressed using a complementation study with a p° 
cell line. As described in the introduction these cells have lost all of their mtDNA but 
not their mitochondria; so with supplementation of certain metabolites, (pyruvate and 
uridine) they can generate ATP, albeit inefficiently, only through glycolysis. We sought 
to develop a p° cell that is of neuronal lineage that can be used in complemenation 
studies. AD cytoplasts can be fused with mt-DNA less cells to produce cybrid cells in 
which to study mtDNA mutational effects.
Ethidium bromide (EtBr) is known to be an inhibitor of mtDNA transcription and 
replication (1 0 2 ) and, thus, limits growth of cells cultured in the presence of the drug. 
The dye induces mtDNA loss by a mechanism that is not entirely understood. The 
selective pressure of the drug on mtDNA replication over nuclear DNA replication is 
believed to be due in part to the topology of mtDNA; mtDNA is a closed circular 
molecule, a structure which induces a high degree of superhelicity (102). With long term 
exposure to EtBr cells may become entirely mtDNA-less, a process we attempted with 
the rat neuronal cell line, PC12.
We used cells that were hypoxanthine-guaninephosphoribosyltransferase-deficient
99
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(HGPRT). For the generation of p° cells, thymidine kinase deficient (TK") cells are 
usually used since a selection process in bromodeoxyuridine (BrdU) is eventually 
performed. Cells that are TK" can survive, since under normal cell growth cells do not 
need TK as the usual means for synthesizing d l'lF  is through dCDP. After cell fusion 
cells are transferred to media containing BrdU but not pyruvate or uridine. Pyruvate and 
uridine are often used to supplement respiratory deficient cells. Uridine is a necessary 
component in pyrimidine biosynthesis. Pyruvate is a key intermediate in a number of 
essential pathways. It can be transaminated to alanine, an essential amino acid used for 
a number of metabolic pathways. Pyruvate can also be carboxylated to oxaloacetate 
inside the mitochondria allowing glucose to be synthesized via glucose 6 -phosphate. The 
p° cells die in the absence of these metabolites and the donor cells do not survive due to 
BrdU. The addition of BrdU will kill the TK+ donor cells as BrdU is phosphorylated 
by TK and is then incorporated into DNA. BrdU has no effect on TK" cells. Thus, only 
fiised cells will grow in this media. Since PC12 (TK ) mutants were not available but 
(HGPRT) mutants were, we reasoned that the latter cell type could still be used if a 
selection was done in 6  thioguanine (6 TG). HGPRT is used in the salvage pathway of 
purine biosynthesis and converts hypoxanthine to IMP and guanine to GMP. In the 
presence of HGPRT the ribose phosphate moiety of 5-phosphoribosyl 1-pyrophosphate 
(PRPP) will be transferred to 6 TG thereby inhibiting cell growth.
Using previously described methods we exposed PC 12 rat neuronal cells to low 
concentrations of EtBr in 12 well polylysine-treated plates. The parameters for EtBr 
sensitivity are however, species (cell) dependent. Nass et al. (102) reported that for
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mouse L-cells and BHK hamster cells 5 ugs/ml of EtBr caused cell death in 8  to 10 days. 
Thus, to get a general range for PC12 sensitivity we did a titration in 0 to 20 ugs of 
EtBr. As can be seen in Fig. 30. up to 800 ngs/ml of the drug had no effect on cell 
viability as compared to the control in three days. A 25 % loss in viability was evident 
for the 2.0 ug/ml concentration. Since the 1000 ng range seemed detrimental to the cells 
we opted for the 100 ng range and initially cultured the cells in 100 and 200 ng/ml EtBr. 
Trounce et al. (136) reported that it took 13 weeks for the osteosarcoma 143BTK- line 
to become mtDNA-less in 50 ngs/ml EtBr. On the other hand, chick embryo fibroblasts 
(CEFs) exposed to 400 ng/ml EtBr were almost p° by week 3 (103). By day 7 since 
viability was similar for control and drug cultures, we increased the drug concentration 
to 500 and 1000 ngs, respectively. We hoped that a higher concentration, similar to the 
CEFs, would induce p° status sooner as long as viability was not compromised.
Cell growth was significantly reduced by day 18, approximately 4-10 fold over 
cells that contained no drug. This was true for the (+ ) EtBr cells without pyruvate and 
uridine (Fig. 31A) as well as with supplementation (Fig. 31B). The addition of pyruvate 
and uridine to cells that contained EtBr did not seem to have any positive effect on cell 
growth (Fig. 31B). This is not entirely unexpected since cells do not become dependent 
on these metabolites until they are almost mtDNA-less. By day 18 this may not be the 
case. The metabolites were included from the outset since they are not detrimental to 
the cells, and, we were unsure as to how long it would take the PC 12 line to become 
mtDNA-less.
While cell growth was perturbed in the cells that contained EtBR, viability was
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Figure 30
SENSITIVITY OF PC 12(HGPRT) CELLS TO ETHIDIUM BROMIDE
Ethidium bromide toxicity of PC 12 (HGPRT) rat cell line. Cells were grown in the drug 
for three days.
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Figure 31
PC12 (HGPRD GROWTH IN ETHIDIUM BROMIDE
Effect of different concentrations of ethidium bromide on PC-12 cell growth. Cell count 
was done in triplicate at 3 day intervals from 12 well plates (A) Cells grown in absence 
of pyruvate and uridine. (B) Cells cultured in presence of pyruvate and uridine.
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not affected for both high and low dye concentrations up to day 13. At this timepoint 
all of the cultures were between 94 and 100% viable (left half Fig. 32). By day 18 
however cell viability was markedly reduced for the control and high drug concentration 
(right half Fig. 32). Viability was reduced for the control to 21% (-P-U), 31% 
(+P +U ), since these cells had grown rapidly as evidenced by the growth profile in Fig 
31 and had begun to die as a result of nutrient depletion. The 1000 ng/ml cell population 
declined to 8 % (-P-XJ), 11 % (+P, +U) viability by day 18. Over an extended period this 
concentration was most likely toxic. On the other hand the viability of the low drug 
group was still quite high, 80% for the -P-U population and 94% for the + P+U  cells.
2. Assesment o f  Mitochondrial DNA Content
The PC 12 cells were assessed for mtDNA content by Southern hybridization. After 
counting of cells at 3 day time points, total DNA was isolated using a proteinase K/SDS 
digestion. The small scale mtDNA isolation was not done since very few cells were 
collected from each well. The isolation represents DNA from live and dead cells. Two 
micrograms of total DNA was loaded per sample on a 0.8 % agarose gel. Purified human 
placental mtDNA prepared by CsCl centrifugation was used as probe. Placental mtDNA 
is extremely homologous to rat mtDNA; thus, we envisioned no problems using placental 
mtDNA. We found that under low stringency hybridization conditions human mtDNA 
shares homology to the lambda DNA that was used as a marker. This was helpful since 
the marker did not have to be hybridized separately. Likewise, since human mtDNA
104
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Figure 32 
PC12 (HGPRT) VIABILITY
Viability of PC 12 cells at day 13 and day 18 of ethidium bromide culture.
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shared homology with lambda, it was possible that the probe would cross react with 
nuclear DNA. This could happen for rat or human mtDNA probes. However, nuclear 
DNA can be expected to be readily digested by the Bam H I; and thus, fragments around 
the same size as mtDNA would be unlikely and thus hybridization negligible. To test 
that the Bam HI enzyme was working properly, a digest of pUC 19 DNA was included 
and digests containing a mixture of pUC19 with some of the PC12 DNA samples. Bam 
HI linearizes pUC 19, and 300 ngs was digested to completion, as assessed on a 0.8% 
agarose gel. pUC 19 plus PC12 DNA samples were also digested to completion 
indicating that there was no inhibitory factors present in the PC 12 DNA isolates (data not 
shown). We then looked at mtDNA content in the PC 12 cells treated with EtBr.
Serial dilutions of purified human placental mtDNA were Bam HI linearized and 
loaded on the same gel as the PC 12 isolates to create a curve that could be used to equate 
optical density with weight. The standard curve was generated by densitometric scanning 
of lanes A to D seen in Fig 33. The weight of mtDNA loaded in each of these lanes 
ranged from 1 to 1000 pgs. As can be seen in the 1000 pg lane, nicked and catenates 
of mtDNA are present in this sample thus it would be erroneous to consider the entire 
1000 pg load weight for the linearized band as yielding a particular OD. Instead, the 
relative percent of the linearized band was used to generate the standard curve. For 
example for the 1000 pg sample, 44% of the DNA was linearized thus .44 x 1000 pg = 
440 pg. The 440 pg and its equivalent OD was used in the standard plot.
Analysis of mtDNA content would have been most helpful for day 18 however 
we performed calculations for day 13. The reason for this is that day 13 viability was
106
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Figure 33
PLACENTAL MtDNA STANDARD CURVE
Standard curve used to estimate mtDNA content. (A). Serial dilutions of human 
placental mtDNA digested with Bam HI - chemiluminescent Southern gel. Probe is 
human placental mtDNA. Bam HI linearizes human mtDNA. Lane A, lOOOpg; lane B, 
100 pg; lane C, 10 pg; lane D, 1 pg. (B). Optical density plot of major species in lanes 
A to D.
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high for all experimental setups (see Fig. 32). By day 18 cell viability was low, thus, 
DNA isolations on this day would consist of live and dead cells. Dead cells would skew 
data since cell lysis and DNA degradation would begin to occur. The Southern blot 
shows that mtDNA is still present in cells grown in the presence of the drug as well as 
controls, as seen in Fig. 34 (A). Three species of bands are visible; the 5 and 11 kb 
bands produced by the Bam digest, and some linearized mtDNA at 16 kb. Optical 
densities for these bands were then used to determine the total weight of mtDNA present. 
To normalize based upon the number of live cells, this total of mtDNA weight was 
divided by cell number. As can be seen in Fig. 34 (B), while the lower drug 
concentration resulted in a slight reduction in mtDNA (.8 x 104 pgs/cell) as compared 
to the control (1.1 x 104), the higher drug concentration seemed to have more 
mtDNA/cell (1.9 x lO-4); thus, by day 13 it would appear that all of the cell lines have 
approximately the same amount of mtDNA. This is not entirely unexpected as some cell 
types can take up to 13 weeks to become mtDNA-less. These cells are currently being 
maintained in EtBr and will be reassessed at a later date for mtDNA content by Southern 
analysis.
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Figure 34
SOUTHERN ANALYSIS OF PC12 MtDNA CONTENT DAY 13
(A) Southern chemiluminescent detection of mtDNA in PC 12 cells treated wtih ethidium 
bromide. Total DNA was isolated, digested with Bam HI and 2 /xg run on a .8% agarose 
gel. Day 13 isolates is shown. Bam HI generates an 11 kb and 5 kb band. Upper most 
band is linearized mtDNA cut at one Bam HI site only. Probe was human mtDNA. 
Seen are Lane A, 1000 ngs/ml drug concentration; lane B, 500 ngs/ml; lane C, 0 ngs/ml.
(B) Calculation of mtDNA content/live cell based on standard curve seen in Fig. 33(B) 
and cell growth curve in Fig. 31(B).














_  w a
t *T
1 o Oo  —



















o o r sTf m
C +
© + - f
109
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER IV DISCUSSION AND CONCLUSIONS
DELETION INVESTIGATION
In an initial analysis, mtDNA isolated from rat brain was examined in order to 
determine if differences in postmortem duration induce non-disease specific degradation 
of mtDNA. We developed this experiment since there was some concern as to the 
different hours of postmortem delay present in our brain samples. Postmortem delay 
refers to the interval between time of death and subsequent time of autopsy. In our case 
this ranged from 5 to 27 hours for the samples obtained from the NNRSB and was not 
available for samples obtained from the Albert Einstein College of Medicine or paraffin 
embedded tissue. Within a few minutes of respiratory arrest a number of pathways 
become activated as the brain responds to oxygen deprivation. This is an important issue 
in the study of mtDNA mutations since one group found that the level of the KSS 
deletion was elevated 8 to 2200 fold in ischemic hearts compared to control hearts (91).
In this study rat brains were removed from the protective skull and placed at RT. 
In actuality, in the human environment the brain remains intact in the skull. Rats were 
sacrificed by decapitation which avoided any complications induced by phenylbarbituate 
inhalation. We found that even after having remained at RT for 30 hours there was no 
gross degradation of mtDNA as evidence by a lack of abnormal migratory bands detected
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by Southern hybridization. In the heart study postmortem time was not the issue but 
changes were observed due to hypoxia. A comparison was made between a control 
group having mean age of 32 years and the ischemic group with an average age of 50 
years (91). Numerous groups have documented an increase in the KSS deletion with age, 
so on this basis alone one would expect that the ischemic group would have an elevated 
percentage of this deletion. This study was later expanded, however, with age matched 
controls and in this case it was reported that a 7 to 220 fold induction in the KSS deletion 
was observed (137). There is, however, a significant difference in the hypoxic state 
present in the heart study versus the hypoxia that occurred immediately following 
decapitation in the rats: this difference is that is the heart study looked at cardiac 
ischemia caused by coronary artery stenois due to arthersclerosis which is a long term 
phenomenon (years) whereas we are looking at a short term effect (hours). Hypoxia may 
induce mtDNA alterations in a chronic condition but have negligible effects otherwise. 
This is supported by studies which find no abnormal neuronal morphology if death occurs 
within several hours (3 to 6) after the initial hypoxic event. Necrosis only becomes 
apparent if an hypoxic event is followed by an extended survival period. Additionally, 
the heart study measured the KSS deletion using PCR whereas we used Southern analysis 
thus, there are differences in sensitivity. However, our purpose was to determine whether 
any macroscopic changes were occurring due to postmortem delay. One other group has 
looked at postmortem effects in a rat brain system using PCR and found no significant
111
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changes. (C. Merril and S. Zullo, personnal communication) (138).
Since the differences in postmortem time did not seem to induce significant 
mtDNA degradation we launched into a study of deletions in AD and aged brain. AD 
is a primary differentiated dementia whereas PD is a neuromuscular disease that has 
dementia as a secondary manifestation. Both diseases lead to degeneration of neurons 
in the CNS while other types of nerve cells are unaffected. A definitive diagnosis for 
AD and PD is usually made at autopsy when characteristic lesions indicative of AD 
(plaques and tangles) or PD (Lewy bodies) are observed (4). Yet, AD and PD lesions 
are often found in association especially in the later stages of the diseases (139). The 
KSS deletion was initially reported to be elevated in the striatum of PD autopsy tissue 
compared to control subjects. This finding is now controversial (140). These results 
suggested that deletions in mtDNA may have a function in PD as well as in a similar 
neurological disorder such as AD. Thus, we undertook a study of deletions in AD. We 
developed a procedure for preparing mtDNA from as little as 50 mg of brain tissue, 
frozen or paraffin embedded. MtDNA was isolated from caudate, parietal cortex, 
hippocampus and temporal cortex. With this procedure mtDNA is readily visualized on 
agarose gels after restriction enzyme digestion without the need for extensive CsCl 
gradient ultracentrifugations. This isolation method would be very helpful in deletion 
analysis where low levels of a deletion are expected. Total DNA isolation often results 
in the need for multiple rounds of PCR up to 65 cycles for deletion analysis (Zullo 
personal communication). With such a high cycle number there is a greater risk of non­
specific amplification. Another benefit of mtDNA enriched isolation is that after digestion
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any residual nuclear DNA is often not present since Bam HI (6 base pair site) and Eco 
RI (6 base pair site) have multiple sites in chromosomal DNA. Southern analysis of 
these agarose gels did not reveal any 11 kb band (indicative of a 5 kb deletion in the 16 
kb mt genome) in any of our brain mtDNA thus, we went to PCR-based methods to 
enhance detection.
A multiplex PCR program indicated that the deletion was indeed present in AD 
and aged brain (105) but it was not present in lymphoblast DNA from patients. This 
latter finding is not necessarily surprising since, if the deletion is harmful, these cells 
would produce fewer daughter cells and eventually the population would be depleted. 
This process would occur in rapidly dividing tissue such as blood. This initial PCR 
result, however, was a qualitative not quantitative finding. Two techniques were 
available for quantitative analysis, SD-PCR and Kinetic PCR. As we worked with these 
two methods we realized that both techniques were susceptible to a number of factors but 
more alarming was the different ratios of deleted mtDNA in the same sample detected 
by both methods. We compared these two widely used methods by determining the 
amount of the KSS deletion (mtDNA*4977) in two regions of the brain from autopsy tissue 
of an individual with lung cancer. For both techniques mtDNA was linearized prior to 
amplification. When mtDNA was not linearized we found that there was greater 
inconsistency of amplification. This may be due to topological constraints induced by 
the circular mitochondrial molecule. Digestion with Bam HI did not seem to inhibit 
amplification; this was most likely due to heat inactivation of the enzyme during the 
initial denaturation step of PCR. However, we did notice while using serial dilution PCR
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that on some occasions the 250 ng dilution reaction using primer pair Jl-KM did not 
amplify well whereas successive lower concentrations did. For the 250 ng reaction, 10 
H1 of a 25 ng//xl DNA digested sample was used. In these instances it appeared that the 
initial sample used for the Bam HI digest was at a low concentration. For a low initial 
DNA concentration, a large volume of the enzyme and digestion buffer would be in the 
250 ng reaction tube. Thus, it seems that in these cases MgCl2 carry over from the 
restriction enzyme buffer may have been inhibiting amplification. Some primer sets are 
extremely sensitive to changes in magnesium concentration. This inhibition was not seen 
for kinetic PCR since only 25 ng of mtDNA was routinely used. Collection of data by 
serial dilution requires determining area by densitometry. We found Ficoll-containing 
dyes simplify scanning by eliminating the smiling effect generated during fast 
electrophoresis. Serial dilution PCR is a non-radioactive method whereas kinetic PCR 
uses labeled nucleotides at very low levels of radioactivity (7 kbq). Area determination 
for kinetic PCR by phosphorimaging is extremely fast and sensitive. There was, 
however, one caveat pertaining to this method; one must have a general idea of the 
deleted range expected in order to determine appropriate cycle time points, otherwise a 
plateau effect can be observed. For both methods it was necessary to test the efficiency 
of the primer pairs used to amplify deleted and normal mtDNA in order to ensure that 
there was not preferential amplification by one set of oligomers.
Measurement of the mtDNAA4977 in the parietal cortex and caudate of the 59 year 
old subject by both methods revealed a greater ratio of deleted mtDNA in the caudate, 
consistent with a report stating that caudate, putamen and striatum have the greatest
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amount of the common 5 kb deletion (141). Soong et al. (141) reported a ratio of 0.0021 
in the caudate of a 57 yr old whereas we detected a ratio of 0.0141 in the caudate of our 
CA subject. Our measurement of the mtDNA44977 in parietal cortex was 0.0014. Corral- 
Debrinski et al. in an analysis of deleted mtDNA in the parietal cortex of aged patients 
reported a range of 0.063% (for a 67 yr old) to 1.2% (for a 77 yr old) as detected by 
serial dilution PCR (142). If we assume that a 59 yr old in their study would have had 
the same amount of deleted mtDNA as the 67 yr old (0.063%), then our 59 yr old CA 
patient had a level of deleted mtDNA (0.14%) that is slightly more than 2-fold higher 
than expected. This level is most probably an underestimation because a number of 
studies indicate that mtDNA deletions typically increase with age, thus the 59 yr old 
would actually be expected to have less than 0.063%. The seeming elevated levels of 
the mtDNA44977 in the caudate and parietal cortex in our sample are interesting, however, 
more CA samples and age matched controls need to be examined before any relationship 
between this cancer patient and defects in mtDNA can be established. We have used this 
CA patient solely as a source of material to provide a comparison of two PCR-based 
techniques commonly used in different laboratories to determine quantitative levels of 
mutant mtDNA.
Using kinetic PCR we arrive at an even greater ratio of the mtDNA44977 in the two 
regions examined. The range previously reported for the mtDNA44977 in striatum using 
kinetic PCR is 0.3% to 5.0%. Comparisons to caudate and parietal cortex is unavailable. 
We have found that, at least in our experience, kinetic PCR which uses a regression line 
to calculate the ratio of deleted to normal mtDNA is extremely sensitive to outliers which
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can significantly skew the regression line and, thus, y-intercept points used to calculate 
the deleted product. However, serial dilution PCR which compares deleted to total 
mtDNA (normal plus mutant) using an optical density curve may be less susceptible to 
such deviations. We believe that serial dilution PCR was the most consistent. For 
example, the 12.5% deleted mtDNA determined by kinetic PCR should have been of 
sufficient amount to have been visible by Southern hybridization. However, we did not 
detect deleted mtDNA by Southern hybridization even after prolonged exposure of the 
film using chemiluminescent detection. Thus, the kinetic PCR method in our hands 
appears to overestimate the amount of deleted mtDNA.
We did not include a comparison to short cycle PCR (143) because this technique 
does not result in a specific percentage of deleted mtDNA that can be compared with the 
other methods.
While the analysis of mtDNA deletions in aging and neuromuscular diseases has 
been greatly accelerated by the use of PCR, this study is the first which indicates that 
PCR-based quantitative methods differ in their effectiveness in measuring mutant mtDNA 
and caution must be exercised in comparing values from different laboratories using 
different techniques.
We concluded that serial dilution PCR was more reliable at least in our experience 
and proceeded to use this method to investigate the KSS deletion in AD brain. We found 
a 12 fold average increase (0.0628% vs 0.0053%,) in mtDNAA4977 in the temporal cortex 
as compared to age matched controls (p =.116 for a one-tailed t-test). If one includes 
two values from the Corral-Debrinski study (110) for the AD group that maintains the
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same mean AD age as our group, then the fold difference is statistically significant for 
both a one-tailed t-test (p=.028) and a two tailed test (p = .057) (see Appendix D). Other 
AD values could not be included because they would increase the AD group mean age. 
Normal values from the Corral-Debrinski study could not be included since they were 
not reported for the temporal cortex.The actual values in AD brain ranged from .007% 
to .2230% while in controls these percentages went from 0.008% to 0.0141 %. When 
we initiated this investigation no other reports on the KSS deletion in AD had been 
reported. Later, as interest in this area expanded sporadic reports surfaced. Corral- 
Debrinski et al. found a ratio of 0.00023 to 0.040 or a percentage of 0.023% to 4.0% 
in temporal cortex of 10 AD patients (111). The average value was 0.007848% or
0.78% which represents a 13 fold difference over the average AD value, 0.0628%, in 
our samples. This could be a reflection of the average ages used in both of these studies 
- our average age was 69 years whereas the Corral-Debrinski study had an average of 
77 years, almost a decade difference. A ten year increase in age especially in the later 
decades often leads to a 20 fold increase in the KSS deletion (142). Our study, then, 
which finds a greater level of the KSS deletion in AD temporal cortex while consisting 
of a small sample size (n=5) is supported by at least one other study (n=10)(lll).
In normal aged brain we found the temporal cortex to have an average percentage 
of 0.0053% of mtDNA"377 while another report found 0.028% There is no comparison 
available for temporal cortex at our average age (69); however, in the Corral-Debrinski 
study a 77 and 94 year old had levels that were 1.2% and 3.4% respectively. This 
would represent a 220 fold difference for a 68 yr old to a 77 yr old. Examination of the
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diagnosis for the 77 yr old control indicated that this subject "showed mild to moderate 
atrophy of the frontal and temporal lobes with hippocampal shrinkage" thus it appears 
as if this does not represent pathologically normal brain tissue and could explain the 220- 
fold difference, in addition to age, between our control group and the 77 yr old value.
Other regions of the cortex have likewise been analyzed for the level of the KSS 
deletion. Blanchard et al. found there was no significant difference in the frontal cortex 
between AD (0.14%) and control subjects (0.12%) (112) while Corral-Debrinski et al 
found a 12-fold difference in this region before age 75 (111). After age 75 the AD 
patients actually had a 4-fold lower level of the deletion in the frontal cortex. The 
authors found this to be a general trend in all cortices - before age 75 the deletion levels 
increased but declined by age 80. Our study then correlates with the before age 75 
results of Corral-Debrinski et al.
It has been hypothesized that mtDNA damage is the result of oxygen radical 
attack. Since free radical damage is believed to increase with advanced age, then in AD 
other factors, environmental or genetic, must be acting in conceit to produce the elevated 
level of mtDNA damage seen in AD. On the other hand, it has been speculated that in 
the 80 yr old group the deletion levels (which start out higher than controls) have 
accumulated such that they begin to induce cell death in AD tissue. Most deletions that 
occur in the "hotspot" region leave the 0 H and 0 L intact, otherwise, these deletions 
would produce sterile genomes (146). Additionally, since the KSS deletion encompasses 
tRNAs, translation is often affected although not transcription. Thus, the deleted 
genomes are replicative competent and, could increase in postmitotic tissue, leading to
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abnormal OXPHOS functioning. This is to differentiate from what may be happening 
in proliferative tissue. Since deletions are heteroplasmic, however, there are normal 
mtDNA available that could compensate for deleterious effects on translation. The 
amount of deletion necessary to induce OXPHOS damage is controversial (144,145) 
ranging from a few percent to 70%. It is our contention that the while the increase in 
mtDNA deletions potentially has adverse effects, it is not the primary event that initiates 
OXPHOS damage in AD brain rather, it may be a genetic defect in free radical 
scavenger systems. This is not to say, however, that therapeutic agents which target 
mtDNA damage would not be helpful in alleviating symptoms of the disease.
We also investigated the minor region of the genome in AD patients for the 
presence of deletions since this region of the genome in relation to neurological disease 
has not been well studied. Whereas the KSS deletion has been found in numerous tissues 
minor region deletions such as mtDNAA361° have only been found in select tissue such as 
skeletal muscle. Are there then tissue specific deletions in brain? We did not detect 
mtDNA'13610 in any of our AD or control brain subjects. This suggests that some 
deletions are indeed tissue specific, implying different mechanisms for the genesis of 
deletions. The prevalent KSS deletion most likely originated during oogenesis or 
embryogenesis (146) whereas mtDNA*3610 may have developed in adult somatic cells. 
While screening the minor region, we identified a fragment that we initially believed 
represented a new deleted mitochondrial genome. Characterization of this fragment 
indicated that it did indeed span a GCTAAG repeat but was actually an artifact of the 
PCR reaction, specifically due to mispriming of the right primer. Alternatively, a
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process known as "jumping PCR" may have resulted in amplification of the deleted band. 
This rather rare event occurs when DNA is damaged in such a way that extension by the 
polymerase is terminated. In this scenario one primer (F2 in this case) initially anneals 
to the correct sequence area but terminates prematurely (at the 3’ end) within the repeat 
site. This aborted product at its 3’ end then jumps and anneals to the second repeat 
sequence causing the generation of a deleted product (54). Either of these two scenarios 
could lead to our results however just simple mispriming is more likely considering the 
potential for complementarity with this primer. Although criteria for this primer were 
met by primer design programs, the observed mispriming denotes the necessity for 
homology searches when using "designing software".
POINT MUTATION ANALYSIS
After the deletion studies we turned our attention to the examination of point 
mutations in the mitochondrial genome. Individuals with the mitochondrial 
encephalomyopathies MERRF and MELAS often present with symptoms such as 
dementia, ataxia and seizures similar to AD. We screened for the MERRF 8344 
tRNAly! mutation and the MELAS 3243 tRNAIcu(UUR) mtDNA mutations and did not find 
any evidence of these alterations in any of our AD samples. However, these are not 
exclusive mutations associated with MERRF and MELAS. Seventy to eighty percent of 
the MERRF cases are due to the 8344 substitution while in a smaller percentage a
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mutation in this same tRNAlyi1 at np 8356 is found (146). Likewise, for MELAS 80% 
of the cases are due to the tRNAlcu(UUR) 3243 mutation and another 10% are caused by a 
mutation in tRNAlcu(UUR) at position 3271 (147). It may be that the low frequency 
mutations are present in AD mtDNA since there seems to be atypical clinical 
presentations associated with the rarer mutations. For instance, the 3243 MELAS 
mutation was also detected in individuals with progressive external ophthalmoplegia 
(PEO), a disease primarily considered to be caused by deletions (148). Alternatively, 
it is possible that other alterations in these tRNAs exist that are unique for AD.
We continued our investigation of point mutations in the mitochondrial genome 
of AD patients - in this instance screening for 2 recently reported AD-associated 
mutations: one in tRNAgln at np 4336 that is moderately conserved and the other mutation 
being in ND1 at np 3397 which alters a highly conserved methionine to valine (85). We 
did not detect the ND1 mutation in any of our samples but we did detect the tRNA8'" 
variant in 4.2% (1/24) of our patient brain tissue and in 0% (0/16) of our control 
subjects. Shoffner et al. found this variant in 3.2% (2/62) AD patients 6.8% (5/73 of 
patients with AD + PD and 5.3% (2/38) of patients with PD for an overall of 5.2% 
(9/173) of patients examined. In the Shoffner et al. study all of the patients were 
Caucasian, thus they looked at the frequency of this variant in the normal Caucasian 
population since specific mtDNA polymorphisms are linked with ethnicity. In the control 
group this value was 0.7% (12/1691). The fact that this mutation is occurring with some 
frequency in controls could mean that this value represents individuals that have not yet 
manifested disease symptoms. This may be the case if the control group is significantly
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younger than the AD group. ( It is not necessary to age match the groups when studying 
point mutations since these do not accumulate in an age specific manner). Another 
theory is that an additional genetic factor, nuclear or mitochondrial, must be present to 
cause predisposition. We were able to obtain race data for a majority of our brain 
samples, especially the AD samples but not for all of the control samples. We detected 
the tRNAgln4336 variant in the temporal cortex of AD #1802, which turned out to be a 
Caucasian subject. Our finding of this mutation in an AD subject supports Shoffner et 
al. ’s initial findings, however we cannot exclude the possibility that detection of this 
mutation merely reflects an ethnic Caucasian variant. However, our percent of the 
affected AD group (4.2%) is very similar to the percent affected found by Shoffner et 
al.(3.2%). The relevance of this mutation remains to be determined by further studies. 
Since this region of the genome seemed to be a hotspot for AD associated mutations at 
least by RFLP analysis we analyzed this region further using SSCP. We detected four 
other mutations at np 3421, 3423, 3480 and 3843, all in ND1. The 3421 mutation is a 
new sequence polymorphism that by itself is a silent mutation but it occurs with 3423 in 
the same patient, AD #1702, and in combination changes a valine to isoleucine.
We continued to use SSCP analysis for mutation detection but focused on 
Complex IV, the cytochrome c oxidase gene, given the biochemical abnormalities 
described earlier in the introduction, including the depressed activity in platelets and in 
cerebral cortex and abnormal COX I, II and III mRNA levels.
SSCP was chosen for mutation detection first because it allows one to screen a 
large number of samples simultaneously (especially when the area to be analyzed covers
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more than one exon) and second, because it lacks the use of hazardous chemicals that is 
often required with other mutation detection techniques such as heteroduplex analysis 
using osmium tetroxide (HOT). Additionally, SSCP does not require expensive 
equipment and the methodology is quite straight forward. However, the technique does 
have limitations, for example requiring the use of relatively small fragment sizes < 300 
bp; we have found that PCR fragments between 200 to 250 base pairs showed the best 
resolution between polymorphic bands. Despite these limitations however, SSCP has 
been widely used in mutation detection since its debut in 1989. Since studies of the 
efficiency of SSCP have ranged from 90% to 60% (127,128,129,130) we decided to 
estimate how efficient the MDE-Hydrolink/glycerol gel was in our screening procedures. 
To obtain this information we sequenced 99 % of the COI and COE from 3 AD patients 
(AD# 3988, 1977, 1816) and the COm gene from 2 AD patients (AD# 3988 and #1977) 
that were previously analyzed by SSCP. For the COEH gene we found no additional 
mutations by sequencing, indicating a 100% efficiency for AD #3988 and #1977. 
Likewise for COE no sequence polymorphisms were detected that did not show single 
strand polymorphisms, indicating 100% efficiency. For the COI gene however, 3 
additional mutations were detected, one in AD #3988 and 2 in AD #1977 but none in 
AD# 1816, thus, the percentage efficiency for each sample in COI was AD #1816, 100% 
(2/2 = 2 detected by SSCP out of 2 total mutations), 66% for AD# 1977 (2/3) and 0% 
for AD #3988 (0/1) giving a mean of 55% for COI. Our total estimation for the 
efficiency of the hydrolink-MDE/10% glycerol gels then, was approximately 80% for all 
three subunits, which represents the number of actual sequence variants/ the number of
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positive SSCPs (8/10). Note our estimation of the efficiency of MDE-hydrolink/10% 
glycerol SSCP gels was determined in a different manner from previous studies. While 
other reports generated percentages by testing known polymorphisms we determined 
whether any unknown mutations escaped detection. Yet, our average efficiency is within 
ranges reported by other groups. Kim et al. report that SSCP efficiency on of 
mitochondrial sequences in the D-loop and in the tRNAilc gene was 75 to 80%. (149).
Calculation of the number of base changes in these three subunits indicates the 
order of increasing variability is COin > COII > COI. Cytochrome c oxidase is the 
terminal complex of the electron transport chain resulting in the reduction of 0 2 to H20, 
oxidation of cytochrome c and transport of protons. COI, COII and COm constitute the 
catalytic core of the Complex IV (150). COm is thought to be involved in proton 
pumping while COO and C01H contain the heme and copper prosthetic groups. COD 
contains the high affinity binding site for cytochrome and recently COm is believed to 
contain a low affinity site (151). Thus it may be that the order of variability in these 
three subunits reflects their individualized relevance in the overall functioning of the 
complex. COin may be more polymorphic than the other subunits since it is not 
involved in substrate interaction whereas COI and COII maintain a more conserved 
structure since they interact with cytochrome c.
We used SSCP to analyze the mtDNA encoded COI, COE and COin subunits of 
Complex IV since there have been an increasing number of studies that suggest a possible 
link between late onset Alzheimer’s Disease and mtDNA mutations. Of the five 
complexes involved in OXPHOS only Complex IV appears to show reduced activity in
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AD. The reason for the altered activity in Complex IV is unknown although a mtDNA 
involvement is supported by a study by Chandrasekaran et al. in which levels of COI and 
COin mRNA in the temporal association cortex of AD brain were decreased [84], The 
12S rRNA, which is transcribed from a H„ promoter that is distinct from the COI, COE 
and COin promoter, was not decreased in the AD subjects, suggesting, that 
transcriptional regulation may be responsible for the decreased cytochrome c oxidase 
activity. However, the major Hs transcript which codes for COI, COE and COm 
transcribes a polycistronic message. This transcript codes for a number of other proteins 
involved in OXPHOS (cytochrome b, ATPase subunits 6 and 8, 7 subunits of NADH 
dehygrogenase) all of which form part of Complexes I, m  and IV. Thus, if regulation 
is occurring at the level of transcription one would expect that other message levels 
would be decreased as well, thereby affecting all of the complexes of the electron 
transport chain complexes. Yet, there do not appear to be any deficiencies in Complex 
I, m  or IV activity in AD brain which would be expected if a transcriptional block 
decreased mitochondrially encoded mRNA for Complex I, m  or IV.
Alternatively, differences in mRNA stability may affect COI and COm mRNA 
levels. A point mutation within the structural genes could affect COI, COD or COm 
mRNA turnover. We identified three missense substitutions, arg9559->pro, val9477-> ile  
and phe9861 ->leu. The first two mutations were previously reported as natural 
polymorphisms; val->ile is one common amino acid change in mtDNA while the 
transversion at 9559 is believed to be indicative of European sequences. We found this 
transversion in a number of our Caucasian samples even though one study reported that
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the prevalence of the 9559 mutation in Europeans was perhaps due to a sequencing error 
(123). The third missense mutation at phe9861 was detected in an AD patient and 
represents a new variant since it has not been observed in any of our controls or in two 
mtDNA data bases which succinctly summarize missense and polymorphic mtDNA 
mutations (124,125). These missense mutations appear to by homoplasmic by sequencing 
and SSCP analysis yet there seem to be conflicting reports as to whether SSCP can detect 
heteroplasmy efficiently (152). RFLP analysis combined with autoradiography can be 
performed to determine heteroplasmy, however, this mutation does not fall within a 
restriction site and would necessitate the use of mismatch PCR to detect this variant. 
Although the phenylalanine at this position is conserved in a number of mammals the 
change to leucine would not appear to dramatically alter the hydrophobicity. However, 
the phe9861 mutation should not be excluded as a possible pathogenic variant until more 
AD and controls have been examined. The need to examine this phe ->  leu mutation 
becomes more evident in view of the observation that a similar phe - > leu alteration 
brought about by a T- > C transition at position 9957 of COin has been found to be 
pathogenic in a progressive mitochondrial encephalomyopathy, hinting, that the aromatic 
ring may have some significance.
Our studies on the cytochrome c oxidase structural genes have not identified 
mutations that might be involved in the increased turnover of mRNA and/or produce an 
improperly translated protein. One possible explanation for this finding is that mutations 
that are not within the genes for COI, COII or COin could be affecting mRNA levels 
in the following manner: human mitochondria are unique from their eukaryotic host in
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that mitochondria contain a compact genome having no introns, rather, mtDNA is 
punctuated by a number of tRNAs. Such a genomic organization implies an extremely 
precise processing event. An enzyme having RNase P-like activity is postulated to play 
a role in producing mature transcripts (153), however the recognition signals along the 
polycistronic message are still unknown as well as whether processing is a sequential or 
simultaneous event. Flanking regions for COI, COO and COEH consist of tRNA’s as well 
as a small intergenic region between COE and COin. Thus, point mutations within 
tRNAs that border COI, COE and COIE could lead to improper splicing events and 
altered mRNA levels. In a preliminary investigation of the region that separates COI and 
COE (7445-7516), we detected a G ->A mutation at bp 7476 in an AD patient that is 
moderately conserved (rat and Xenopus). The H„ transcript for this region does not code 
for a mature tRNA, however, the light strand transcript codes for tRNAUCNscr. Yet, 
processing within this region does occur for the H„ transcript and a point mutation here 
would not only alter the tRNA but could affect the mRNA processing events that lead 
to mature COI, COE and COIE mRNA. Thus, tRNA sequences between the CO subunits 
should be further investigated.
One aspect of AD research that investigators should not lose sight of is that 
whether heritable, sporadic, late or early onset all AD patients manifest similar 
neuropathology, that is, plaques and tangles. The different forms of the disease may 
originate at individual branches but at some point these paths must converge along a 
similar route that leads to neuronal degeneration. Could altered oxidative metabolism, 
produce the hallmark characteristics of AD? If the electron transport chain is defective
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then ATP production driven by the proton motive force would be decreased. Parker et 
al describe two scenarios as a result of defective ATP production (154). Low ATP levels 
may induce certain metabolic processes among them, protein kinase activation which may 
in turn cause abnormal protein phosphorylation such as that seen in NFTs. Activation of 
bovine protein kinases has been shown to be induced by low ATP levels Furthermore, 
a deficient respiratory chain would lead to the accumulation of specific products or 
reactants. For instance, if Complex IV is perturbed then molecular oxygen 
concentrations may become elevated. The reaction of electrons with 0 2 could produce 
oxygen radicals. Interestingly one study found that free radicals can induce cross-linking 
of tyrosly hydroxyl groups in the amyloid peptide potentially leading to aggregate 
formation (155). Thus, it is possible that free radicals and subsequent damage they 
induce in AD are either (a) due to increased production of oxygen radicals or (b) due to 
an inability to cope with normal production.
RHO ZERO STUDY
Our investigation of mtDNA in AD as well as other groups’ have begun to detect 
variants of the mitochondrial genome present in some cases of AD. The tRNA81"4336 that 
has been reported to be associated with 3.2% of AD cases was detected in 4.2% of our 
AD cases supporting this initial study. We detected a novel variant, COin9861, in 
approximately 4% of our AD cases that alters a phe-> leu at codon 219. The question
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as to whether this and other identified mutations are indeed pathogenic in AD or, even 
to discern whether mitochondrial DNA defects in general lead to the OXPHOS problems 
seen in AD could be addressed using an alternate strategy; the use of a p° cell line would 
be most helpful in this regard. As described in the introduction these cells have lost all 
of their mtDNA but not their mitochondria so with supplementation of certain 
metabolites, (pyruvate and uridine) they can generate ATP, albeit inefficiently.
The p°206 cell line (a derivative of the bromodeoxyuridine resistant 143B.TK' cell line) 
has been complemented with mtDNA from patients carrying the mitochondrial 
encephalomyopathy mtDNA mutations for MERRF and MELAS. While the p°206 cell 
line provides one system for the study of AD associated mtDNA mutations, we believed 
that a p° investigation would be more beneficial if one used a cell type that was similar 
to the cell population affected in AD, i.e. a neuronal-like cell type. A neuronal mtDNA- 
less cell fine can be used to transfer aberrant mtDNA carrying a specific mutation or it 
can be used to transfer mtDNA from a patient with no identified mutation. This latter 
study would at the very least give information on whether mtDNA plays any role in the 
disease. Thus, we embarked on a study aimed at developing a neuronal p° cell fine 
through the use of ethidium bromide (EtBr). We chose the rat neuronal cell line PC12 
since it has been well characterized by many groups, is used in numerous AD studies that 
examine amyloid deposition in AD, and lastly, because it has the excellent property of 
neuritic differentiation upon addition of NGF.
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Similar to other drug studies, EtBr slowed cell growth of PC12 (HGPRT) cells 
although not cell viability at 100 and 200 ng/ml. By day 13 Southern analysis indicated 
mtDNA content was similar in all control and drug treated cells. After analyzing the 
effects of EtBr on cell growth, viability, and mtDNA content, one well from each 
experimental group was expanded into 10 cm petri dishes and the EtBr concentration was 
reduced back to 100 and 200 ng/ml since the higher drug concentrations were toxic upon 
extended exposure. These cells are currently being maintained in culture. For the future 
we plan to select clones of cells that are growing in discrete colonies on the petri dishes, 
an approach used by Trounce et al (136). Colonies represent cells that are either EtBr 
resistant or are surviving passage into the p° genotype. Petri dishes are ideal technically 
for colony seletion with adherent cells since dead cells detach from the plate and can be 
easily removed. MtDNA content from discrete populations grown in petri dishes at 
week 10 or 15 will probably provide a better assessment of p° status. The p° PC12 cell 
line can then be used in cybrid studies with AD mitochondria carrying the tRNA 4336 
mutation as well as the COm 9861 mutation. In addition it would prove very interesting 
to ascertain how these mtDNA-less cells respond to NGF. The p° PC 12 would yield 
valuable information not only on the process of neurite outgrowth but on the involvement 
of mtDNA in AD, in the latter case either indicating mtDNA mutations are pivotal or 
opening the door to the study of nuclear encoded respiratory chain subunits.
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APPENDIX A
L i s t  o f  Postmortem B r a i n  T i s s u e  s h I P MF N T  R F P O R T
Suppl ied  by W.K. T o u r t e l l o t t e ,  M.D. ,  Ph.D.  a m . J MLI i J—
D i r e c t o r
Na t i on a l  N e u r o l o g i c a l  R e s e a r c h  Specimen Bank Nat as ha  S. Hamblet
H S B # AGE D I A G N O S I S 2 -L C S T R U C T U R E A U T O L Y S I S A M O U
S E X TI ME ( H R S . ) (CMS
1546 75/M Alzheimer ' s 10 c au d a t e 8.0 0.9
10 temporal  cortex • 0.9
1 4 h ip poc am pus  * 0 4
14 parietal cortex 0.6
1556 BI/M Alzheimer ' s 9 ca u d a t e 7.5 0.6
6 temporal  cortex • 0.5
11 parietal cortex • 0.4
1573 79/M Alzheimer ' s 16 ca ud a t e 7 .0 0.7
16 temporal  cortex • 1.1
7 parietal cortex • 0.7
1607 80/F Alzheimer ' s 4 c au d a t e 5.5 0.3
6 temporal  cortex • 0.5
10 parietal cortex • 0.9
1630 86/F Alzheimer ' s 5 c a u d a t e  • 7.0 0.8
5 temporal  cortex • 0.5
10 parietal cortex * 0.5
' 7 0 2 76/F Alzheimer ' s 4 ca ud a t e 5.5 1 . 0
11 parietal con e x  • 0.5
1674 84/F Alzheimer ' s 3 c au o a t e 6.0 0.6
1 1 parietal cortex • 0.9
1647 76/M Alzheimer ' s 8 c au o a t e 5.0 0.5
8 temporal  cortex • 0 5
8 h i pp oc am pu s  . 0.5
12 parietal cortex • 0.3
1739 78/M Alzheimer ' s 7 c au d a t e 8.0 0.5
7 temporal  cortex • 0.6
10 h ip poc am pu s  • 0.8
12 parietal cortex * 0.4
1765 77/M Alzheimer ' s 9 c a u o a t e 5.5 0.7
9 temporal  cortex * 0.6
13 parietal cortex * 0.6
1770 75/M Alzheimer ' s 8 ca u d a t e 8.5 0.4
8 temporal  cortex • 0.5
15 parietal cortex • 0.8
1802 65/F Alzheimer ' s 5 c au d a t e 6 .5 1.2
5 temporal  cortex • 0.4
10 panetal  cortex 0.8
1807 75/M Alzheimer ' s 5 c au da t e 5.5 0 7
5 temporal cortex • 0 5
12 parietal cortex 0.7
316 89/F Alzheimer ' s 7 ca u d a t e  • 7.5 0 9
7 ' t empora l  cortex * 0.5
1 1 . h i pp oca m pus  . 0.3
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S H I P M E N T  R E P Q R
Natasha  S. Hamblet
H S B #  A G E D I A G N O S I S S T R U C T U R E A U T O L Y S I S A M O U N
S E X TI ME ( H R S  1 LQ.MS)
i  7 parietal c o r t e x . 1.0
1974 e5 / c Alzheimer ' s 8 c a u d a t e 7 0.7
6 temporal  cortex • 0.8
15 parietal cor tex • 1.0
1977 81/F Alzheimer ' s 6 c a u d a t e 5 0.6
7 temporal  c o r t e x . 0.4
1 3 h iQpocampus  . 0.6
15 parietal cor tex » 1.0
1327 52/M Control 1 6 parietal cortex 19 1.8
1341 48/M Control 13 parietal cortex 9 1 2
1347 66/M Control 1 5 parietal cortex 9 0.7
1350 59/M Control 1 i parietal cortex 7 0.8
1351 59/M Control 6 c a u o a t e '9 0.3
6 temporal  c on ex 0.4
1 1 parietal cortex 0.4
1355 58/M Control 5 c a u d a t e 9.5 0.3
5 temporal  conex 0.7
1401 59/M Control 12 - ^ h i p p o c a m p u s 23 0.5
1 7 parietal co ne x 1.0
1406 40/M Control g c a u d a t e 16 0.5
9 temporal  c on ex 0.3
16 parietal c on ex 0.6
1413 67/M Control 4 temporal  c on ex 22 0.6
15 parietal cor tex 0.5
1415 59/M Control 8 ca u d a t e 11 0.8
1 5 panetal  c o n e x 0.8
1441 64/M Control 15 parietal co n ex 10 0.7
1539 68/M Control 9 temporal  cortex 16.5 0.3
12 parietal cortex 1.1
1569 61/M Control 8 temporal  cortex 9 0.3
19 parietal cortex 0.9
1640 66/M Control 5 c a u d a t e 15.5 0.7
15 parietal cortex 0.6
1818 59/M Control 6 temporal  cortex 15 0.8
1 4 parietal cortex 0.5
1846 73/M Control 8 c a u d a t e 26.5 1.2
8 temporal  cortex 0.9
1 t parietal con ex 1.2
1903 70/M Control 8 c a u d a t e 13 0.9
8 temporal  c on ex 1.0
15 parietal c one x 1.2
1933 38/M Control 8 ca u d a t e 15 0.2
146
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
S H I P M S H I - .  RE PO RT
H S B * 






Na tas ha  S. Hamblet
AGE
£12
D I AGNOS I S £ ic
15
S T R U C T U R E
h i p p o c a m p u s  
parietal  conex
A U T O L Y S I S  
TI ME ( HRS. I
A M O U N T









D I A G N O S I S  S E C  S ’ R U C T U R E
Alzheimer ' s  8 S 9  c a u o a t e
8 temporal  conex
i a  p ane i a l  cortex
i 5 pane ia l  cortex
Alzheimer ' s  6 c a u o a t e
8 tempora l  conex
12 h i p p o c a m p u s
16 pane t a i  conex
Alzheimer ' s  7 c a u o a t e
7 temporal  conex
15 parietal  conex
Alzheimer ' s  7 c a u o a t e
7 temporal  cortex
11 parietal  conex
Alzheimer ' s  8 c a u d a t e
8 temporal  cortex




























Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX B
Autopsy Samples Received: Dr. Peter Davies 
Albert Einstein College of Medicine
CASE AGE(yrs) NEUROPATHOLOGY DIAGNOSIS
3822 67 AD:sparing limbic system and brain stem, amyloid 
angiopathy, cerebellar plaques
3929 90 AD: plaques-only type,atherosclerotic and 
hypertensive vascular disease
3988 85 AD: plaques only type, hypertensive vascular 
disease, lacunar infarcts (mixed dementia)
4073 92 AD: athersclerotic vascular disease, hypertensive 
vascular disease, lacunar infarcts
4299 64 AD:arthersclerotic vascular disease, 
leukoencephalopathy,amyloid angiopathy
4308 76 AD: amyloid angiopathy, leukoencephalopathy, 
cerebellar plaques, microinfarcts
4390 65 AD: hyperacute anoxic-ischemic changes, 
cerebral cortical dysplasia
4395 60 AD: amyloid angiopathy, cerebellar plaques
4460 80 AD: amyloid angiopathy, cerebellar and basal 
ganglia plaques, Lewy bodies compatible with PD
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APPENDIX C
Lymphocyte Cell Lines 
Alzheimer’s Disease Research Centers National Cell Repository
Cell Line if Age(yrs) Description
200 71 Married In
938 85 Married In
890 70 Married In
767 89 Married In
915 67 Married In
291 71 Biopsy Confirmed AD
38 85 Probable AD
36 70 Probable AD
135 89 Probable AD
617 67 Possible AD
347 60 Offspring Of Affected
105 41 Offspring Of Affected
835 58 Offspring Of Affected
628 43 Offspring of Affected
863 50 Offspring of Affected
429 27 Normal
1079 32 Normal
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APPENDIX D
Table 4 QUANTITATION OF mtDNA4’77 IN THE TEMPORAL CORTEZ
GROUP 1 GROUP 2 
ALZHEIMER'S CONTROL
CASE # AGE % DELETED CASE # AGE % DELETED
1537 64 .0070 1569 61 .0079
1802 65 .2230 1413 67 .0014
694 68 .0141 1539 68 .0013
576 72 .0560 1903 70 .0141
1807 75 .0138 1846 73 .0016
A.2* 63 .3000
A.4* 72 .3600
Mean Age: 68.4 yrs
Mean % mtDNA4977: 
.1391%
s2 = .023
Mean Age: 68 yrs
Mean % mtDNA4977: 
.0053%
s2 = .00003
* Corral-Debrinski et al. 1994.
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